EP2185178A2 - Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity - Google Patents
Use of an fgf-21 compound and a glp-1 compound for the treatment of obesityInfo
- Publication number
- EP2185178A2 EP2185178A2 EP08796800A EP08796800A EP2185178A2 EP 2185178 A2 EP2185178 A2 EP 2185178A2 EP 08796800 A EP08796800 A EP 08796800A EP 08796800 A EP08796800 A EP 08796800A EP 2185178 A2 EP2185178 A2 EP 2185178A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- cys
- glp
- fgf
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title claims abstract description 214
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title claims abstract description 214
- 150000001875 compounds Chemical class 0.000 title claims abstract description 128
- 208000008589 Obesity Diseases 0.000 title claims abstract description 33
- 235000020824 obesity Nutrition 0.000 title claims abstract description 33
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title claims description 18
- 238000011282 treatment Methods 0.000 title claims description 16
- -1 GLP-1 compound Chemical class 0.000 claims abstract description 122
- 230000037396 body weight Effects 0.000 claims abstract description 38
- 102000037865 fusion proteins Human genes 0.000 claims description 35
- 108020001507 fusion proteins Proteins 0.000 claims description 35
- 150000001413 amino acids Chemical group 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 108060003951 Immunoglobulin Proteins 0.000 claims description 15
- 102000018358 immunoglobulin Human genes 0.000 claims description 15
- HPJLZFTUUJKWAJ-JHEQGTHGSA-N Glu-Gly-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HPJLZFTUUJKWAJ-JHEQGTHGSA-N 0.000 claims description 6
- GNRMAQSIROFNMI-IXOXFDKPSA-N Phe-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O GNRMAQSIROFNMI-IXOXFDKPSA-N 0.000 claims description 6
- HWLKHNDRXWTFTN-GUBZILKMSA-N Pro-Pro-Cys Chemical compound C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CS)C(=O)O HWLKHNDRXWTFTN-GUBZILKMSA-N 0.000 claims description 6
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 claims description 6
- LYMVXFSTACVOLP-ZFWWWQNUSA-N Trp-Leu Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C([O-])=O)=CNC2=C1 LYMVXFSTACVOLP-ZFWWWQNUSA-N 0.000 claims description 6
- KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 claims description 6
- 108010080629 tryptophan-leucine Proteins 0.000 claims description 6
- YJIUYQKQBBQYHZ-ACZMJKKPSA-N Gln-Ala-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YJIUYQKQBBQYHZ-ACZMJKKPSA-N 0.000 claims description 4
- LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 claims description 4
- DUTMKEAPLLUGNO-JYJNAYRXSA-N Lys-Glu-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DUTMKEAPLLUGNO-JYJNAYRXSA-N 0.000 claims description 4
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims description 4
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 claims description 4
- 108010077515 glycylproline Proteins 0.000 claims description 4
- 108010077112 prolyl-proline Proteins 0.000 claims description 4
- 108010051110 tyrosyl-lysine Proteins 0.000 claims description 4
- PUBLUECXJRHTBK-ACZMJKKPSA-N Ala-Glu-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O PUBLUECXJRHTBK-ACZMJKKPSA-N 0.000 claims description 2
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 claims description 2
- MFMDKJIPHSWSBM-GUBZILKMSA-N Ala-Lys-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFMDKJIPHSWSBM-GUBZILKMSA-N 0.000 claims description 2
- ZUVMUOOHJYNJPP-XIRDDKMYSA-N Arg-Trp-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZUVMUOOHJYNJPP-XIRDDKMYSA-N 0.000 claims description 2
- BVLIJXXSXBUGEC-SRVKXCTJSA-N Asn-Asn-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVLIJXXSXBUGEC-SRVKXCTJSA-N 0.000 claims description 2
- WQLJRNRLHWJIRW-KKUMJFAQSA-N Asn-His-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)N)N)O WQLJRNRLHWJIRW-KKUMJFAQSA-N 0.000 claims description 2
- JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 claims description 2
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 claims description 2
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 claims description 2
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
- AQPZYBSRDRZBAG-AVGNSLFASA-N Gln-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N AQPZYBSRDRZBAG-AVGNSLFASA-N 0.000 claims description 2
- HMIXCETWRYDVMO-GUBZILKMSA-N Gln-Pro-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O HMIXCETWRYDVMO-GUBZILKMSA-N 0.000 claims description 2
- OXEMJGCAJFFREE-FXQIFTODSA-N Glu-Gln-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O OXEMJGCAJFFREE-FXQIFTODSA-N 0.000 claims description 2
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 claims description 2
- KASDBWKLWJKTLJ-GUBZILKMSA-N Glu-Glu-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O KASDBWKLWJKTLJ-GUBZILKMSA-N 0.000 claims description 2
- UHVIQGKBMXEVGN-WDSKDSINSA-N Glu-Gly-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UHVIQGKBMXEVGN-WDSKDSINSA-N 0.000 claims description 2
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 claims description 2
- AAJHGGDRKHYSDH-GUBZILKMSA-N Glu-Pro-Gln Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O AAJHGGDRKHYSDH-GUBZILKMSA-N 0.000 claims description 2
- BPCLDCNZBUYGOD-BPUTZDHNSA-N Glu-Trp-Glu Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 BPCLDCNZBUYGOD-BPUTZDHNSA-N 0.000 claims description 2
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 claims description 2
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 claims description 2
- MAABHGXCIBEYQR-XVYDVKMFSA-N His-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N MAABHGXCIBEYQR-XVYDVKMFSA-N 0.000 claims description 2
- OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 claims description 2
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 claims description 2
- BKTXKJMNTSMJDQ-AVGNSLFASA-N Leu-His-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N BKTXKJMNTSMJDQ-AVGNSLFASA-N 0.000 claims description 2
- UHNQRAFSEBGZFZ-YESZJQIVSA-N Leu-Phe-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N UHNQRAFSEBGZFZ-YESZJQIVSA-N 0.000 claims description 2
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 claims description 2
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 claims description 2
- KWUKZRFFKPLUPE-HJGDQZAQSA-N Lys-Asp-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWUKZRFFKPLUPE-HJGDQZAQSA-N 0.000 claims description 2
- MWVUEPNEPWMFBD-SRVKXCTJSA-N Lys-Cys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCCN MWVUEPNEPWMFBD-SRVKXCTJSA-N 0.000 claims description 2
- ODUQLUADRKMHOZ-JYJNAYRXSA-N Lys-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N)O ODUQLUADRKMHOZ-JYJNAYRXSA-N 0.000 claims description 2
- ISHNZELVUVPCHY-ZETCQYMHSA-N Lys-Gly-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O ISHNZELVUVPCHY-ZETCQYMHSA-N 0.000 claims description 2
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 claims description 2
- PBLLTSKBTAHDNA-KBPBESRZSA-N Lys-Gly-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PBLLTSKBTAHDNA-KBPBESRZSA-N 0.000 claims description 2
- AFLBTVGQCQLOFJ-AVGNSLFASA-N Lys-Pro-Arg Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AFLBTVGQCQLOFJ-AVGNSLFASA-N 0.000 claims description 2
- CAVRAQIDHUPECU-UVOCVTCTSA-N Lys-Thr-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAVRAQIDHUPECU-UVOCVTCTSA-N 0.000 claims description 2
- RQILLQOQXLZTCK-KBPBESRZSA-N Lys-Tyr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O RQILLQOQXLZTCK-KBPBESRZSA-N 0.000 claims description 2
- RKIIYGUHIQJCBW-SRVKXCTJSA-N Met-His-Glu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O RKIIYGUHIQJCBW-SRVKXCTJSA-N 0.000 claims description 2
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 claims description 2
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 claims description 2
- IIEOLPMQYRBZCN-SRVKXCTJSA-N Phe-Ser-Cys Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O IIEOLPMQYRBZCN-SRVKXCTJSA-N 0.000 claims description 2
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 claims description 2
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 claims description 2
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 claims description 2
- SEZGGSHLMROBFX-CIUDSAMLSA-N Pro-Ser-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O SEZGGSHLMROBFX-CIUDSAMLSA-N 0.000 claims description 2
- UEJYSALTSUZXFV-SRVKXCTJSA-N Rigin Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UEJYSALTSUZXFV-SRVKXCTJSA-N 0.000 claims description 2
- OYEDZGNMSBZCIM-XGEHTFHBSA-N Ser-Arg-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OYEDZGNMSBZCIM-XGEHTFHBSA-N 0.000 claims description 2
- LTFSLKWFMWZEBD-IMJSIDKUSA-N Ser-Asn Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O LTFSLKWFMWZEBD-IMJSIDKUSA-N 0.000 claims description 2
- VAUMZJHYZQXZBQ-WHFBIAKZSA-N Ser-Asn-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O VAUMZJHYZQXZBQ-WHFBIAKZSA-N 0.000 claims description 2
- ZOHGLPQGEHSLPD-FXQIFTODSA-N Ser-Gln-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZOHGLPQGEHSLPD-FXQIFTODSA-N 0.000 claims description 2
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 claims description 2
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 claims description 2
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 claims description 2
- CUTPSEKWUPZFLV-WISUUJSJSA-N Thr-Cys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(O)=O CUTPSEKWUPZFLV-WISUUJSJSA-N 0.000 claims description 2
- LAFLAXHTDVNVEL-WDCWCFNPSA-N Thr-Gln-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O LAFLAXHTDVNVEL-WDCWCFNPSA-N 0.000 claims description 2
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 claims description 2
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 claims description 2
- RWOKVQUCENPXGE-IHRRRGAJSA-N Tyr-Ser-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RWOKVQUCENPXGE-IHRRRGAJSA-N 0.000 claims description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 claims description 2
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 claims description 2
- 108010047857 aspartylglycine Proteins 0.000 claims description 2
- 108010060199 cysteinylproline Proteins 0.000 claims description 2
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 claims description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 claims description 2
- 108010049041 glutamylalanine Proteins 0.000 claims description 2
- 108010051307 glycyl-glycyl-proline Proteins 0.000 claims description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims description 2
- 108010015792 glycyllysine Proteins 0.000 claims description 2
- 108010073472 leucyl-prolyl-proline Proteins 0.000 claims description 2
- 108010057821 leucylproline Proteins 0.000 claims description 2
- 108010064235 lysylglycine Proteins 0.000 claims description 2
- 108010070643 prolylglutamic acid Proteins 0.000 claims description 2
- 101001032756 Rattus norvegicus Granzyme-like protein 1 Proteins 0.000 claims 13
- 238000000034 method Methods 0.000 abstract description 42
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 224
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 171
- 102100040918 Pro-glucagon Human genes 0.000 description 171
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 159
- 238000006467 substitution reaction Methods 0.000 description 59
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 57
- 108010011459 Exenatide Proteins 0.000 description 32
- 229960001519 exenatide Drugs 0.000 description 32
- 235000001014 amino acid Nutrition 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 23
- 230000004048 modification Effects 0.000 description 19
- 238000012986 modification Methods 0.000 description 19
- 239000000203 mixture Substances 0.000 description 17
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 description 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 15
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 13
- 229920001223 polyethylene glycol Polymers 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 10
- 239000000556 agonist Substances 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 230000002195 synergetic effect Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 208000016261 weight loss Diseases 0.000 description 9
- 230000004580 weight loss Effects 0.000 description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 6
- 108091006905 Human Serum Albumin Proteins 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 102000004338 Transferrin Human genes 0.000 description 6
- 108090000901 Transferrin Proteins 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 125000002843 carboxylic acid group Chemical group 0.000 description 6
- 238000007385 chemical modification Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000012581 transferrin Substances 0.000 description 6
- 238000007792 addition Methods 0.000 description 5
- 230000006320 pegylation Effects 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 238000007126 N-alkylation reaction Methods 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 3
- 229960004733 albiglutide Drugs 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000006240 deamidation Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 108700027806 rGLP-1 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010966 qNMR Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to compositions that comprise an FGF-21 compound and a GLP-I compound. These compositions can be used to lower body weight and treat obesity.
- Fibroblast growth factor 21 belongs to a family of large polypeptides widely expressed in developing and adult tissues that play crucial roles in multiple physiological functions.
- FGF-21 has been reported to stimulate glucose-uptake in mouse adipocytes after prolonged treatment, in the presence and absence of insulin, and to decrease fed and fasting blood glucose, triglycerides, and glucagon levels in ob/ob and db/db mice in a dose-dependent manner, thus, providing the basis for the use of FGF-21 as a therapy for treating diabetes and obesity (WO03/011213).
- Glucagon-like peptide- 1 (GLP-I) compounds have been described for the treatment of obesity. (WO98/019698). Although both FGF-21 and GLP-I compounds have shown positive effects in treating obesity, there has not been any indication that a combination of FGF-21 compounds and GLP-I compounds would provide a synergistic effect on lowering body weight. There is thus, still a need for additional beneficial therapeutics for weight loss.
- the present invention relates to compositions comprising a FGF-21 compound and a GLP-I compound.
- the present invention also provides a method of lowering body weight comprising administering an FGF-21 compound in combination with a GLP-I compound.
- the present invention provides a method of treating obesity comprising administering a FGF-21 compound in combination with a GLP-I compound.
- the present invention also provides compositions comprising a FGF-21 compound and an exendin compound.
- the present invention also provides a method of lowering body weight comprising administering an FGF-21 compound in combination with an exendin compound.
- the present invention provides a method of treating obesity comprising administering a FGF-21 compound in combination with an exendin compound.
- a “FGF-21 compound” is defined as a compound comprising native human FGF- 21 (SEQ ID NO: 2), an FGF-21 analog, or an FGF-21 derivative.
- the FGF-21 compounds of the present invention retain FGF-21 activity as measured in assays as described in Kharitonenkov, et ⁇ /.,(Journal of Clinical Investigation, 115(6): 1627 (2005)).
- a "FGF-21 analog” is defined as a molecule having a modification including one or more amino acid substitutions, deletions, inversions or additions when compared with SEQ ID NO: 2.
- a "FGF-21 derivative” is defined as a molecule having the amino acid sequence of human FGF-21 (SEQ ID NO : 2) or of a FGF-21 analog but additionally having at least one chemical modification of one or more of its amino acid side groups, ⁇ -carbon atoms, terminal amino group, or terminal carboxylic acid group. Modifications at amino acid side groups include acylation of lysine e-amino groups, N-alkylation of arginine, histidine, or lysine, alkylation of glutamic or aspartic carboxylic acid groups, and deamidation of glutamine or asparagine.
- Modifications of the terminal amino include the des-amino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications.
- Modifications of the terminal carboxy group include the amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications.
- a lower alkyl is a C i-C 4 alkyl.
- one or more side groups, or terminal groups may be protected by protective groups known to the ordinarily-skilled protein chemist.
- the ⁇ -carbon of an amino acid may be mono-or di- methylated.
- the chemical modification may also include "pegylation.”
- GLP-I compound is defined as a compound comprising the amino acid sequence of native human GLP-I (SEQ ID NO: 3), a GLP-I analog or GLP-I derivative, which maintains GLP-I activity.
- GLP-I activity may be measured by methods known in the art, including using in vivo experiments and in vitro assays that measure GLP-I receptor binding activity or receptor activation, e.g., assays employing pancreatic islet cells or insulinoma cells, as described in EP 619,322, Gelfand, et ai, and U.S. Patent No. 5,120,712, respectively.
- GLP-I compounds are well known in the art. See, e.g. PCT International Application Publication Nos. WO 03/040309, U.S. patent Nos. 6,593,295, 7,141,547, and 7,176,278.
- GLP-I analog is defined as a molecule having a modification including one or more amino acid substitutions, deletions, inversions, or additions when compared with SEQ ID NO: 3.
- GLP-I analog also includes "GLP-I fusion proteins" where the GLP-I fusion protein is a heterologous protein comprising a GLP-I or GLP-I analog and a second polypeptide selected from the group consisting of human albumin, human albumin analogs, fragments of human albumin, transferrin, transferrin analogs, transferrin derivatives, fragments of transferring, the Fc portion of an immunoglobulin, an analog of the Fc portion of an immunoglobulin, and fragments of the Fc portion of an immunoglobulin, and wherein the C-terminus of the first polypeptide is fused to the N- terminus of the second polypeptide.
- the GLP-I or GLP-I analog may be fused to the second polypeptide via a peptide linker.
- the GLP-I fusion proteins of the present invention contain an Fc portion which is derived from human IgG4 but comprises one or more substitutions compared to the wild-type human sequence (SEQ ID NO: 5).
- a "GLP-I derivative" is defined as a molecule having the amino acid sequence of native human GLP-I or of a GLP-I analog, but additionally having at least one chemical modification of one or more of its amino acid side groups, a-carbon atoms, terminal amino group, or terminal carboxylic acid group.
- Modifications at amino acid side groups include acylation of lysine e-amino groups, N-alkylation of arginine, histidine, or lysine, alkylation of glutamic or aspartic carboxylic acid groups, and deamidation of glutamine or asparagine.
- Modifications of the terminal amino include the des-amino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications.
- Modifications of the terminal carboxy group include the amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications.
- a lower alkyl is a C ⁇ -C 4alkyl.
- one or more side groups, or terminal groups may be protected by protective groups known to the ordinarily-skilled protein chemist.
- the ⁇ -carbon ofan amino acid may be mono-or di-methylated.
- the chemical modification may also include the pegylation of an amino acid of the peptide or polypeptide.
- the nomenclature used herein to refer to specific GLP-I analogs and GLP-I derivatives is defined as follows: Specific substitutions to a GLP-I analog and GLP-I derivative are indicated using the specific amino acid being substituted followed by the residue number.
- GLP-l(7-37) indicates that the GLP-I analog portion of the mature fusion protein begins with His at position 7 and ends with Gly at position 37.
- exendin compound is defined as a compound comprising the amino acid sequence of exendin-4 (SEQ ID NO: 4), an exendin-4 analog or exendin-4 derivative, wherein the exendin compound maintains exendin-4 activity.
- exendin-4 analog is defined as a compound having a modification including one or more amino acid substitutions, deletions, inversions, or additions when compared with the amino acid sequence of exendin-4 (SEQ ID NO: 4).
- Exendin-4 analog also includes “exendin fusion proteins” where the "exendin fusion protein” is a heterologous protein comprising an exendin-4 or exendin-4 analog and a second polypeptide selected from the group consisting of human albumin, human albumin analogs, fragments of human albumin, transferrin, transferrin analogs, transferrin derivatives, fragments of transferring, the Fc portion of an immunoglobulin, an analog of the Fc portion of an immunoglobulin, and fragments of the Fc portion of an immunoglobulin, and wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide.
- exendin-4 or exendin-4 analog may be fused to the second polypeptide via a peptide linker.
- the exendin-4 fusion proteins of the present invention may contain an Fc portion which is derived from human IgG4 but comprises one or more substitutions compared to the wild-type human sequence (SEQ ID NO: 5).
- An "exendin-4 derivative" is defined as a compound having the amino acid sequence of exendin-4 or of an exendin-4 analog, but additionally having at least one chemical modification of one or more of its amino acid side groups, a-carbon atoms, terminal amino group, or terminal carboxylic acid group.
- Modifications at amino acid side groups include acylation of lysine e-amino groups, N-alkylation of arginine, histidine, or lysine, alkylation of glutamic or aspartic carboxylic acid groups, and deamidation of glutamine or asparagine.
- Modifications of the terminal amino include the des-amino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications.
- Modifications of the terminal carboxy group include the amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications.
- a lower alkyl is a C i-C 4alkyl.
- one or more side groups, or terminal groups may be protected by protective groups known to the ordinarily-skilled protein chemist.
- the ⁇ -carbon of an amino acid may be mono-or di- methylated.
- the chemical modification may also include pegylation.
- the Fc portion of an immunoglobulin has the meaning commonly given to the term in the field of immunology. Specifically, this term refers to an antibody fragment which does not contain the two antigen binding regions (the Fab fragments) from the antibody.
- the Fc portion consists of the constant region of an antibody from both heavy chains, which associate through non-covalent interactions and disulfide bonds.
- the Fc portion can include the hinge regions and extend through the CH2 and CH3 domains to the c-terminus of the antibody.
- the Fc portion can further include one or more glycosylation sites.
- the fusion proteins described herein may also contain a linker ("L").
- the linker may comprise the sequence Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 6).
- the number immediately preceding the L refers to the number of linkers separating the particular peptide or protein portion from the Fc portion.
- a linker specified as 1.5L refers to the sequence Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly- Gly-Gly-Ser-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 7).
- IgG4 refers to an analog of the human IgG4 Fc sequence specified as SEQ ID NO: 5. Substitutions in the IgG4 Fc portion of the fusion protein are indicated in parenthesis.
- the wild-type amino acid is specified by its common abbreviation followed by the position number in the context of the entire IgG4 sequence using the EU numbering system followed by the amino acid being substituted at that position specified by its common abbreviation.
- PEG polyethylene glycol or a derivative thereof as are known in the art.
- PEG is a linear polymer with terminal hydroxyl groups and has the formula HO-CH 2 CH 2 - (CH 2 CH 2 O)W-CH 2 CH 2 -OH, where n is from about 8 to about 4000.
- the terminal hydrogen may be substituted with a protective group such as an alkyl or aryl group.
- PEG has at least one hydroxy group, more preferably it is a terminal hydroxy group. It is this hydroxy group which is preferably activated to react with the peptide.
- PEG useful for the present invention. Numerous derivatives of PEG exist in the art and are suitable for use in the invention.
- the PEG molecule covalently attached to compounds in the present invention is not intended to be limited to a particular type.
- PEG'S molecular weight is preferably from 500-100,000 daltons and more preferably from 20,000-60,000 daltons and most preferably from 20,000-40,000 daltons.
- PEG may be linear or branched.
- “In combination with” or “coadministration” refers to the administration of a FGF- 21 compound with a GLP-I compound either simultaneously, sequentially or a combination thereof.
- the combination therapy of a FGF-21 compound with a GLP-I compound results in a synergistic effect in lowering body weight and thus, in the treatment of obesity.
- the combination therapy also results in a synergistic effect on lower elevated blood glucose levels and thus, a potential use in the treatment of diabetes.
- effect refers to a loss in body weight, lowering of body weight or a reduction in blood glucose levels.
- the FGF-21 compounds, the GLP-I compounds and the exendin compounds of the present invention may be made using various techniques known to one of skill in the art.
- the FGF-21, GLP-I and exendin compounds may be made using recombinant techniques.
- DNA sequences of mature human FGF-21 SEQ ID NO: 1
- native GLP-I native GLP-I
- exendin-4 PCR methodology may be used to isolate genes encoding the corresponding gene.
- one of skill in the art is aware of various methods to introduce changes in the DNA sequence so as to effect desired changes in the amino acid sequence of the resulting FGF-21 , GLP- 1 or exendin compounds.
- the GLP-I and the exendin peptides of the present invention can also be prepared by using standard methods of solid-phase peptide synthesis techniques.
- Peptide synthesizers are commercially available from, for example, Applied Biosystems in Foster City, Calif. Reagents for solid phase synthesis are commercially available, for example, from Midwest Biotech (Fishers, Ind ).
- Solid phase peptide synthesizers can be used according to manufacturer's instructions for blocking interfering groups, protecting the amino acid to be reacted, coupling, decoupling, and capping of unreacted amino acids.
- a wide variety of methods have been described in the art to covalently conjugate PEGs to peptides (for review article see, Roberts, M. et al.
- Pegylation of peptides at the carboxy-terminus may be performed via enzymatic coupling using recombinant compounds of the present invention as a precursor or alternative methods known in the art and described. See e.g. U.S. Patent 4,343,898 or InternationalJ ⁇ urnal of Peptide & Protein Research.43A27-38, 1994.
- Various methods of protein purification may be employed and such methods are known in the art and described, for example, in Deutscher, Methods in Enzymology 182: 83-9 (1990) and Scopes, Protein Purification: Principles and Practice, Springer- Verlag, NY (1982).
- the purification step(s) selected will depend on the nature of the production process used and the particular protein produced.
- fusion proteins comprising an Fc fragment can be effectively purified using a Protein A or Protein G affinity matrix.
- Low or high pH buffers can be used to elute the fusion protein from the affinity matrix. Mild elution conditions will aid in preventing irreversible denaturation of the fusion protein.
- Coadministration of FGF-21 compounds, GLP-I compounds and exendin compounds of the present invention may be via any route known to be effective by the physician of ordinary skill.
- Peripheral parenteral is one such method. Parenteral administration is commonly understood in the medical literature as the injection of a dosage form into the body by a sterile syringe or some other mechanical device such as an infusion pump. Peripheral parenteral routes can include intravenous, intramuscular, subcutaneous, and intraperitoneal routes of administration. Those skilled in the art can readily optimize pharmaceutically effective dosages and administration regimens for the combinations of the present invention, as determined by good medical practice and the clinical condition of the individual patient.
- a typical dose range for the FGF-21 compounds of the present invention will range from about 0.01 mg per day to about 1000 mg per day for an adult.
- a typical dose range for the GLP-I derivative compounds of the present invention will range from about 0.01 mg per day to about 1000 mg per day for an adult.
- doses may be in the range of 0.01 to 1 mg/kg body weight, preferably in the range of 0.05 to 0.5 mg/kg body weight.
- the present invention provides a composition comprising a FGF-21 compound and a GLP-I compound.
- the present invention provides a composition comprising a FGF-21 compound and a GLP-I compound, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the GLP-I compound is selected from the group consisting of GLP-I analog, GLP-I derivative and GLP-I fusion proteins.
- the composition comprises an FGF- 21 analog and a GLP-I analog.
- the composition comprises a FGF-21 analog and a GLP-I derivative.
- the composition comprises a FGF-21 analog and a GLP-I fusion protein.
- the present invention provides a composition comprising an FGF-21 compound and an exendin compound.
- the composition comprises a FGF-21 compound and an exendin compound, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the exendin compound is selected from the group consisting of exendin-4, an exendin-4 analog, an exendin-4 derivative, and an exendin-4 agonist.
- the composition comprises a FGF-21 analog and exendin-4.
- the composition comprises a FGF-21 analog and an exendin-4 analog.
- the composition comprises a FGF-21 analog and an exendin-4 derivative.
- the composition comprises a FGF-21 analog and an exendin-4 agonist.
- the present invention also provides a method of lowering body weight comprising administering a FGF-21 compound in combination with a GLP-I compound.
- administering a FGF-21 compound in combination with a GLP-I compound results in a synergistic effect on weight loss.
- the method of lowering body weight comprises administering a FGF-21 compound in combination with a GLP-I compound, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the GLP-I compound is selected from the group consisting of GLP-I analog, GLP-I derivative and GLP-I fusion protein.
- the method of lowering body weight comprises administering a FGF-21 analog in combination with a GLP-I analog.
- the method of lowering body weight comprises administering a FGF-21 analog in combination with a GLP-I derivative.
- the method of lowering body weight comprises administering a FGF-21 analog and a GLP-I fusion protein.
- the present invention also provides a method of lowering body weight comprising administering a FGF-21 compound in combination with an exendin compound.
- administering a FGF-21 compound in combination with an exendin compound results in a synergistic effect on weight loss.
- the method of lowering body weight comprises administering a FGF-21 compound in combination with an exendin compound, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the exendin compound is selected from the group consisting of exendin-4, an exendin-4 analog, an exendin-4 derivative, and an exendin-4 agonist.
- the method of lowering body weight comprises administering a FGF-21 analog in combination with exendin-4. In another preferred embodiment, the method of lowering body weight comprises administering a FGF-21 analog in combination with an exendin-4 analog. In another preferred embodiment, the method of lowering body weight comprises administering a FGF-21 analog and an exendin-4 derivative. In another preferred embodiment, the method of lowering body weight comprises administering a FGF-21 analog and an exendin-4 agonist.
- the present invention also provides a method of treating obesity comprising administering a FGF-21 compound in combination with a GLP-I compound.
- administering a FGF-21 compound in combination with a GLP-I compound results in a synergistic effect on weight loss.
- the method of treating obesity comprises administering a FGF-21 compound in combination with a GLP-I compound, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the GLP-I compound is selected from the group consisting of GLP-I analog, GLP-I derivative and GLP-I fusion protein.
- the method of treating obesity comprises administering a FGF-21 analog in combination with a GLP-I analog. In another preferred embodiment, the method of treating obesity comprises administering a FGF-21 analog in combination with a GLP-I derivative. In another preferred embodiment, the method of treating obesity comprises administering a FGF-21 analog and a GLP-I fusion protein.
- the present invention also provides a method of treating obesity comprising administering a FGF-21 compound in combination with an exendin compound.
- administering a FGF-21 compound in combination with an exendin compound results in a synergistic effect on weight loss.
- the method of treating obesity comprises administering a FGF-21 compound in combination with an exendin compound, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the exendin compound is selected from the group consisting of exendin-4, an exendin-4 analog, an exendin-4 derivative, and exendin-4 agonist.
- the method of treating obesity comprises administering a FGF-21 analog in combination with exendin-4. In another preferred embodiment, the method of treating obesity comprises administering a FGF-21 analog in combination with an exendin-4 analog. In another preferred embodiment, the method of treating obesity comprises administering a FGF-21 analog and an exendin-4 derivative. In another preferred embodiment, the method of treating obesity comprises administering a FGF-21 analog and an exendin-4 agonist.
- the present invention also provides for the use of a FGF-21 compound and a GLP-I compound in the manufacture of a medicament to lower body weight.
- the present invention also provides for the use of a FGF-21 compound and a GLP-I compound in the manufacture of a medicament to lower body weight, wherein the FGF-21 compound i s selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the GLP-I compound is selected from the group consisting of a GLP-I analog, a GLP-I derivative and a GLP-I fusion protein.
- the present invention provides for the use of a FGF-21 analog and a GLP-I analog in the manufacture of a medicament to lower body weight.
- the present invention provides for the use of a FGF-21 analog and a GLP-I derivative in the manufacture of a medicament to lower body weight.
- the present invention provides for the use of a FGF-21 analog and a GLP-I fusion protein in the manufacture of a medicament to lower body weight.
- the present invention also provides for the use of a FGF-21 compound and an exendin compound in the manufacture of a medicament to lower body weight.
- the present invention also provides for the use of a FGF-21 compound and an exendin compound in the manufacture of a medicament to lower body weight, wherein the FGF- 21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the exendin compound is selected from the group consisting of exendin-4, an exendin-4 analog, an exendin-4 derivative, and an exendin-4 agonist.
- the present invention provides for the use of a FGF- 21 analog and an exendin-4 analog in the manufacture of a medicament to lower body weight. In another preferred embodiment, the present invention provides for the use of a FGF-21 analog and an exendin-4 derivative in the manufacture of a medicament to lower body weight. In another preferred embodiment, the present invention provides for the use of a FGF-21 analog and an exendin-4 agonist in the manufacture of a medicament to lower body weight.
- the present invention also provides for the use of a FGF-21 compound and a GLP-I compound in the manufacture of a medicament for the treatment of obesity.
- the present invention also provides for the use of a FGF-21 compound and a GLP- 1 compound in the manufacture of a medicament for the treatment of obesity, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the GLP-I compound is selected from the group consisting of a GLP-I analog, a GLP-I derivative and a GLP-I fusion protein.
- the present invention provides for the use of a FGF-21 analog and a GLP-I analog in the manufacture of a medicament for the treatment of obesity.
- the present invention provides for the use of a FGF-21 analog and a GLP-I derivative in the manufacture of a medicament for the treatment of obesity. In another preferred embodiment, the present invention provides for the use of a FGF-21 analog and a GLP-I fusion protein in the manufacture of a medicament for the treatment of obesity.
- the present invention also provides for the use of a FGF-21 compound and an exendin compound in the manufacture of a medicament to treat obesity.
- the present invention also provides for the use of a FGF-21 compound and an exendin compound in the manufacture of a medicament to lower body weight, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF- 21 derivative and wherein the exendin compound is selected from the group consisting of exendin-4, an exendin-4 analog, an exendin-4 derivative, and an exendin-4 agonist.
- the present invention provides for the use of a FGF-21 analog and an exendin-4 analog in the manufacture of a medicament to treat obesity.
- the present invention provides for the use of a FGF-21 analog and an exendin-4 derivative in the manufacture of a medicament to treat obesity. In another preferred embodiment, the present invention provides for the use of a FGF-21 analog and an exendin-4 agonist in the manufacture of a medicament to treat obesity.
- the FGF-21 compounds of the present invention may be human FGF-21, a FGF- 21 analog or a FGF-21 derivative.
- the FGF-21 compound of the present invention is a FGF-21 analog.
- the present invention provides FGF-21 compounds comprising one or two engineered disulfide bonds.
- the present invention provides FGF-21 compounds which comprise an amino acid sequence comprising a cysteine substitution at positions 21, 26, 33, 118, 119, 121, 122, or 134 of FGF-21 (SEQ ID NO: 2).
- the FGF-21 compound comprises an amino acid sequence comprising an amino acid substitution at position 167 of FGF-21 (SEQ ID NO: 2), wherein the substitution is not Ser or Tyr.
- the FGF-21 compound comprises an amino acid sequence comprising an amino acid substitution at position 121 of FGF-21 (SEQ ID NO: 2), wherein the substitution is any amino acid except Gln or Asn.
- the amino acid at position 121 of FGF-21 (SEQ ID NO: 2) is selected from the group consisting of Ala, VaI, Ser, Asp, or Glu.
- the FGF-21 compound comprises an amino acid sequence selected from the group consisting of Cys m -Cys 134 -FGF-21 (SEQ ID NO: 9), Cys 118 -Cys 134 -Ala 167 -FGF-21 (SEQ ID NO: 10), Cys 21 -Cys 33 -Ala 167 -FGF-21 (SEQ ID NO: 11), Cys 26 -Cys m -Ala 167 - FGF-21 (SEQ ID NO: 12), and Cys M8 -Cys 134 -Ala 121 - Ala 167 -FGF-21 (SEQ ID NO: 13).
- the FGF-21 compound consists of an amino acid sequence selected from the group consisting of Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9), Cys 118 -Cys 134 -Ala 167 -FGF-21 (SEQ ED NO: 10), Cys 21 -Cys 33 -Ala 167 -FGF-21 (SEQ ID NO: 11), Cys 26 -Cys 122 -Ala 167 - FGF-21 (SEQ ID NO: 12), and Cys 118 -Cys 134 -Ala 121 -Ala I67 -FGF-21 (SEQ DD NO: 13).
- the present invention provides FGF-21 compounds which consist of a cysteine substitution at positions 21, 26, 33, 118, 119, 121, 122, or 134 of FGF-21 (SEQ ID NO: 2).
- the FGF-21 compound consist of an amino acid substitution at position 167 of FGF-21 (SEQ ID NO: 2), wherein the substitution is not Ser or Tyr.
- the FGF-21 compound consists of a substitution at position 121 of FGF-21 (SEQ ID NO: 2), wherein the substitution is any amino acid except Gln or Asn.
- the amino acid at position 121 of FGF-21 (SEQ ID NO: 2) is selected from the group consisting of Ala, VaI, Ser, Asp, or Glu.
- the FGF-21 compound consists of an amino acid sequence selected from the group consisting of Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9), Cys 118 -Cys 134 -Ala 167 -FGF-21 (SEQ ID NO: 10), Cys 21 -Cys 33 -Ala 167 -FGF-21 (SEQ ID NO: 11), Cys 26 -Cys 122 -Ala 167 - FGF-21 (SEQ ID NO: 12), and Cys 118 -Cys 134 -Ala 12I -Ala 167 -FGF-21 (SEQ ID NO: 13).
- the present invention provides GLP-I compounds to be used in combination with the FGF-21 compounds of the present invention.
- the GLP-I compound is a GLP-I analog, GLP-I derivative, or a GLP-I fusion protein.
- the GLP-I compound is a GLP-I analog or derivative.
- the GLP-I compound is a GLP-I analog.
- the GLP-I compound comprises of an amino acid sequence of SEQ ID NO: 14
- Xaa at position 8 is Gly, Ala, VaI, Xaa at position 22 is Gly, Glu, Asp, or Lys, Xaa at position 33 is VaI, or He, Xaa at position 34 is Lys or Arg, Xaa at position 36 is Arg or Gly, Xaa at position 37 is selected from the group consisting of NH2, Gly and Pro, Xaa at position 38 is Ser or absent, Xaa at position 39 is Ser or absent, Xaa at position 40 is Gly or absent, Xaa at position 41 is Ala or absent, Xaa at position 42 is Pro or absent, Xaa at position 43 is Pro or absent, Xaa at position 44 is Pro or absent, and Xaa at position 45 is Ser or absent.
- the GLP-I compound comprises Ala at Xaa 8 . In another embodiment, the GLP-I compound comprises VaI at Xaag. In another embodiment, the GLP-I compound comprises Gly at Xaa22. In a preferred embodiment, the GLP-I compound comprises Gly at Xaa22- In a preferred embodiment, the GLP-I compound comprises Lys at Xaa34. In another preferred embodiment, the GLP-I compound comprises Arg at Xaa 34 .
- the amino acid sequence of the GLP-I analog comprises Val 8 -Glu 22 - ⁇ e 33 -Gly ⁇ -Pro ⁇ -Se ⁇ -Sei ⁇ '-Gly ⁇ -Ala ⁇ -Pro ⁇ -Pro ⁇ -Pro ⁇ -Ser 45 - GLP-I (SEQ ID NO: 19).
- the amino acid sequence of the GLP-I analog consists of Val ⁇ Glu ⁇ -Ue ⁇ -Gly ⁇ -Pro ⁇ -Se ⁇ Se ⁇ -Gly ⁇ -Ala ⁇ -Pro ⁇ -Pro ⁇ -Pro 44 - Ser 45 -GLP-1 (SEQ ID NO: 19).
- the amino acid sequence of the GLP-I compound comprises Val 8 -GLP-1 (SEQ ED NO: 15). In a preferred embodiment, the amino acid sequence of the GLP-I compound consists of the amino acid sequence Val 8 -GLP-1 (SEQ ID NO: 15). In another preferred embodiment, the amino acid sequence of the GLP-I compound comprises Arg ⁇ -GLP-l (SEQ ID NO: 16). In another preferred embodiment, the amino acid sequence of the GLP-I compound consists of Arg 34 -GLP-1 (SEQ ED NO: 16). In another preferred embodiment, the amino acid sequence of the GLP-I compound comprises Val 8 -Glu 22 -GLP-1 (SEQ ED NO: 17).
- the amino acid sequence of the GLP-I compound consists of Val 8 -Glu 22 -GLP-1 (SEQ ED NO: 17).
- the amino acid sequence of VaI 8 -Glu 22 -GLP- 1 comprises of five additional amino acid sequence substitutions.
- the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) consists of five additional amino acid sequence substitutions.
- the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) comprises of four additional amino acid sequence substitutions.
- the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) consists of four additional amino acid sequence substitutions.
- the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) comprises of three additional amino acid sequence substitutions.
- the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) consists of three additional amino acid sequence substitutions.
- the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) comprises of two additional amino acid sequence substitutions.
- the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) consists of two additional amino acid sequence substitutions.
- the amino acid sequence of Val 8 -Glu 22 - GLP-I comprises of one additional amino acid sequence substitution.
- the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) consists of one additional amino acid sequence substitution.
- the present invention also provides GLP-I derivatives in combination with FGF- 21 compounds.
- the GLP-I derivative is pegylated.
- the GLP-I derivative comprises of an amino acid sequence of SEQ ID NO: 20
- Xaa at position 8 is: D-Ala, Gly, VaI, Leu, lie, Ser, or Thr; 17
- Xaa at position 22 is: Gly, Glu, Asp, or Lys; Xaa at position 33 is: VaI or He Xaa at position 46 is: Cys or CyS-NH 2 and wherein one PEG molecule is covalently attached to Cys 45 and one PEG molecule is covalently attached to Cys 46 or Cys 46 -NH2.
- the GLP-I derivative consists of the amino acid sequence of SEQ ID NO:20.
- Xaag is VaI or Gly.
- Xaa 22 is Gly or Glu.
- Xaa33 is He.
- Xaa ⁇ is CyS-NH 2 .
- the GLP-I derivative comprises of the amino acid sequence of Val 8 -Glu 22 -Ile 33 -Cys-NH 2 46 -GLP- 1 (SEQ ID NO: 21 ).
- the GLP-I derivative consists of the amino acid sequence of Val 8 -Glu 22 -Ile 33 -Cys-NH 2 4 ⁇ - GLP-I (SEQ ID NO: 21).
- the GLP-I compound is a GLP-I fusion protein.
- the GLP-I fusion protein comprises a GLP-I portion and an Fc portion of an immunoglobulin.
- the GLP-I fusion protein comprises a GLP-I analog and the Fc portion of an immunoglobulin wherein the GLP-I analog comprises an amino acid sequence of SEQ ID NO: 22
- Xaa at position 8 is Gly or VaI
- Xaa at position 33 is VaI or Lys
- Xaa at position 34 is Lys or Asn
- Xaa at position 37 is Gly, Pro or is absent, and wherein the GLP analog is fused to the Fc portion of an immunoglobulin comprising the amino acid sequence of Formula IV (SEQ ID NO: 23)
- Xaa at position 16 is Pro or Glu
- Xaa at position 17 is Phe, VaI, or Ala
- Xaa at position 18 is Leu, Glu, or Ala
- Xaa at position 80 is Asn or Ala
- Xaa at position 230 is Lys or is absent.
- the C-terminus of the GLP-I analog and the N- terminus of the Fc portion of an immunoglobulin are preferably fused together via 1, 1.5 (SEQ ID NO: 7) or 2 repeats (SEQ ID NO: 8) of a G-rich peptide linker having the sequence Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 6).
- the GLP-I fusion protein comprises a GLP-I analog and the Fc portion of an immunoglobulin wherein the GLP-I analog consists of an amino acid sequence of SEQ BD NO: 22 and wherein the GLP analog is fused to the Fc portion of an immunoglobulin consisting of the amino acid sequence of SEQ ID NO: 23.
- the GLP-I fusion protein further comprises a linker.
- the GLP-I fusion protein further comprises a linker, wherein the linker comprises an amino acid sequence is selected from the group consisting of SEQ ID NO: 6, SEQ BD NO:7 and SEQ BD NO:8.
- the GLP-I fusion protein further comprises a linker, wherein the linker consists of an amino acid sequence is selected from the group consisting of SEQ DD NO: 6, SEQ DD NO:7 and SEQ BD NO:8.
- the linker comprises an amino acid sequence of SEQ ED NO:6.
- the linker comprises an amino acid sequence of SEQ ID NO:7.
- the linker comprises an amino acid sequence of SEQ BD NO: 8.
- the linker consists of an amino acid sequence of SEQ ID NO:6. In an embodiment, the linker consists of an amino acid sequence of SEQ ID NO:7. In an embodiment, the linker consists of an amino acid sequence of SEQ ID NO 8
- the GLP-I portion comprises Gly at Xaa8. In another embodiment, the GLP-I portion comprises VaI at Xaa ⁇ . In an embodiment, the GLP-I portion comprises Gly at Xaa22- In a preferred embodiment, the GLP-I portion comprises Glu at Xaa 22 - In an embodiment, the GLP-I portion comprises Ly s at Xaa 3 4. In another embodiment, the GLP-I portion comprises Asn at Xaa 34 . In an embodiment, Xaa 37 of the GLP-I portion is absent. In a preferred embodiment, the GLP- 1 portion comprises Gly at Xaa3 7 . In another preferred embodiment, the GLP-I portion comprises Pro at Xaa 37 .
- GLP-I fusion proteins of the present invention include the following proteins: Gly 8 -Glu 22 -Gly 36 -GLP-1-lL-IgG4 (S228P) (SEQ ID NO: 24), Gly 8 -Glu 22 - Gly 36 -GLP-1-lL-IgG4 (S228P, F234A, L235A) (SEQ ID NO: 25), Gly 8 -Glu 22 -Gly 36 - GLP-1-lL-IgG4 (S228P, N297A) (SEQ ID NO: 26), Gly 8 -Glu 22 -Gly 36 -GLP-1-lL-IgG4 (S228P, F234A, L235A, N297A) (SEQ ID NO: 27), Gly 8 -Glu 22 -Gly 36 -GLP-1-lL-IgG4 (S228P, des K) (SEQ ID NO: 28), Gly 8 -Glu 22 -Gly 36
- GLP-1-2L-IgG4 (S228P, F234A, L235A, des K) (SEQ ID NO: 45)
- Gly 8 -Glu 22 -Gly 36 - GLP-1-2L-IgG4 (S228P, N297A, des K)
- SEQ ID NO: 46 Gly 8 -Glu 22 -Gly 36 -GLP-1-2L- IgG4
- SEQ ID NO: 47 Gly 8 -Glu 22 -Gly 36 -GLP-1-2L- IgG4
- the present invention also includes FGF-21 compounds in combination with
- GLP-I compounds wherein the GLP-I compound comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57.
- the present invention also includes FGF-21 compounds in combination with GLP-I compounds, wherein the GLP-I compound consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57.
- Preferred FGF-21 compound and GLP-I compound combinations of the present invention include, Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with VaI 8 - GLP-I (SEQ ID NO: 15), Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17), Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with is Val 8 -Glu 22 -Ile 33 -Gly 36 -Pro 37 -Ser 38 -Ser 39 -Gly 40 -Ala 41 -Pro 42 -Pro 43 - Pro ⁇ -Ser ⁇ -GLP-KSEQ ID NO: 19), Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with pegylated Val 8 -Glu 22 -Ile 33 -Cys-NH
- Cys 134 -FGF-21 in combination with Gly 8 -Glu 22 -Gly 36 -GLP-1 -IL-Ig(M (S228P, des K) (SEQ ID NO: 28), Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with Gly 8 -Glu 22 -Gly 36 -GLP-1-lL-IgG4 (S228P, F234A, L235A, des K) (SEQ ID NO: 29), Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with Gly 8 -Glu 22 -Gly 36 -GLP- l-lL-IgG4 (S228P, N297A, des K) (SEQ ID NO: 30), Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with Gly 8 -Glu 22 -Gly 36 -GLP-1 -
- Glu 22 -Gly 36 -GLP-1-2L-IgG4 (S228P, F234A, L235A, N297A, des K) (SEQ ID NO: 47), Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with exendin-4 (SEQ ID NO: 4), Cys m -Cys 134 -FGF-21 (SEQ K) NO: 9) in combination with albiglutide (SEQ ID NO: 48).
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 -Cys !34 -FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with five additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys 118 - Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with five additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val 8 -Glu 22 - GLP-I (SEQ ID NO: 17) with four additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys 118 -Cys 134 -FGF-21 (SEQ ED NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with four additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with three additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9) in 25
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 - Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with two additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of VaI 8 - Glu 22 -GLP-1 (SEQ ID NO: 17) with two additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with one additional amino acid sequence substitution.
- the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys 118 -Cys 134 -FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with one additional amino acid sequence substitution.
- More preferred FGF-21 compound and GLP-I compound combinations of the present invention include Cys 1 I8 -Cys 134 -Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with Val 8 -GLP-1 (SEQ ID NO: 17), Cys 118 -Cys 134 -Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with Vaf-Glu ⁇ -GLP-l (SEQ DD NO: 17), Cys 118 -Cys l34 -Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with is Val 8 -Glu 22 -Ile 33 -Gly 36 -Pro 37 -Ser 38 -Ser 39 -Gly 40 - Ala 41 -Pro 42 -Pro 43 -Pro 44 -Ser 45 -GLP-1(SEQ DD NO: 19), Cys 1I8 -Cys 134 -Ala 167 -FGF-21 (SEQ ID NO:
- GLP-I (SEQ ID NO: 18), Cys m -Cys 134 -Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with Gly 8 -Glu 22 -Gly 36 -GLP-l(7-37)-lL-IgG4 (S228P) (SEQ ID NO: 24), Cys 118 -Cys 134 - Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with Gly 8 -Glu 22 -Gly 36 -GLP-l(7-37)-lL- IgG4 (S228P, F234A, L235A) (SEQ ED NO: 25), Cys 118 -Cys 134 -Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with Gly 8 -Glu 22 -Gly 36 -GLP-l(7-37)-lL-IgG4 (S228P, N297A) (
- GLP-1-2L-IgG4 (S228P, F234A, L235A) (SEQ ID NO: 41)
- Cys 118 -Cys 134 -Ala 167 -FGF- 21 (SEQ ID NO: 10) in combination with Gly 8 -Glu 22 -Gly 36 -GLP-1-2L-IgG4 (S228P, N297A) (SEQ ID NO: 42)
- Cys m -Cys 134 -Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with Gly 8 -Glu 22 -Gly 36 -GLP-l(7-37)-2L-IgG4 (S228P, F234A, L235A, N297A) (SEQ ID NO: 43)
- Cys m -Cys 134 -Ala 167 -FGF-21 (SEQ ID NO:10) in combination with Gly 8 -Glu 22 -Gly 36 -G
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 -Cys 134 -Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ED NO: 17) with five additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys M8 -Cys 134 -Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with five additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 -Cys 134 - 29
- the combination of the present invention comprises an FGF -21 analog consisting of the amino acid sequence of Cys 118 -Cys 134 -Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with four additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 -Cys 134 - Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP- 1 analog comprises an amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with three additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys 118 -Cys 134 -Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP-I analog consist of an amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with three additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 -Cys !34 - Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP- 1 analog comprises the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with two additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys 118 -Cys 134 -Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with two additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 -Cys 134 - Ala 167 -FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP- 1 analog comprises the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with one additional amino acid sequence substitution.
- the combination of the present invention comprises an FGF-21 analog consisting of the 30
- Preferred FGF-21 compound and GLP-I compound combinations of the present invention include, Cys 118 -Cys 134 -Ala 121 -Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with VaI 8 -GLP-l (SEQ ID NO: 15), Cys 118 -Cys 134 -Ala 121 -Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17), Cys 118 -Cys 134 -Ala 121 - Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with is Val 8 -Glu 22 -Ile 33 -Gly 36 -Pro 37 - Ser ⁇ Se ⁇ -Gly ⁇ -Ala ⁇ -Pro ⁇ -Pro ⁇ -Pro ⁇ -Ser ⁇ -GLP-l (SEQ ID NO: 19), Cys 118 -Cys 134 - Ala 121 -A
- Cys m -Cys 134 -Ala m -Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with Gly 8 -Glu 22 - Gly 36 -GLP-1-1.5L-IgG4 (S228P, F234A, L235A) (SEQ ID NO: 33), Cys 118 -Cys 134 - Ala 121 -Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with Gly 8 -Glu 22 -Gly 36 -GLP-1- 1.5L-IgG4 (S228P, N297A) (SEQ ID NO: 34), Cys 118 -Cys 134 -Ala 121 -Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with Gly 8 -Glu 22 -Gly 36 -GLP-1-1.5L-IgG4 (S228P, F234A, L235A, N297A)
- Cys 134 -Ala 121 -Ala 167 -FGF-21 in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 54, Cys n8 -Cys 134 -Ala 121 -Ala 167 - FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 55, Cys 118 -Cys 134 -Ala 121 -Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 55, Cys 118 -Cys 134 -Ala 121 -Ala 167 -FGF-21 (SEQ ID NO: 13) in 33
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 -Cys 134 -Ala !21 -Ala 167 -FGF- 21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with five additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys 118 -Cys 134 -Ala 121 -Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with a GLP- 1 analog, wherein the GLP- 1 analog consists of the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with five additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 - Cys 134 -Ala 121 -Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val 8 -Glu 22 -GLP-l (SEQ ID NO: 17) with four additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys 118 -Cys 134 -Ala 121 -Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with four additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 -Cys l34 -Ala 12I -Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val 8 -Glu 22 - GLP-I (SEQ ID NO: 17) with three additional amino acid sequence substitutions.
- the combination of the present invention comprises an 34
- FGF-21 analog consisting of the amino acid sequence of Cys m -Cys 134 -Ala 121 -Ala 167 - FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with three additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 -Cys 134 -Ala 121 -Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with two additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys 118 -Cy s 134 - Ala 121 -Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) with two additional amino acid sequence substitutions.
- the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys 118 -Cys 134 -Ala 121 -Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val 8 -Glu 22 -GLP-1 (SEQ ID NO: 17) comprises one additional amino acid sequence substitution.
- the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys 118 -Cys 134 -Ala 121 -Ala 167 -FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val 8 -Glu 22 - GLP-I (SEQ ID NO: 17) comprises one additional amino acid sequence substitution.
- Example 1 Effect of combination treatment with GLP-I and FGF-21 on body weight and on blood glucose levels
- DIO Diet-induced obese (DIO) male C57/B16 mice (Harlan: Virginia) maintained on a calorie rich diet (TD95217, Teklad, Madison, WI) since weaning are used. DIO is established by ad libitum feeding for at least 7 weeks of a diet consisting of 40% fat, 39% carbohydrate, and 21% protein caloric content (TD95217). Animals are individually housed in a temperature-controlled (24°C) facility with 12 hour light/dark cycle (lights on 35
- mice are randomized according to their body weight, so each experimental group of animals would have similar body weight.
- Body composition of DIO male C57/B16 mice is determined by using QNMR analysis 1 day prior to initiation of treatment. Combination treatment is administered with two delivery methods.
- a FGF-21 compound (1 mg/kg) is subcutaneously injected once a day and a GLP-I compound (3 nmol/kg/day) is delivered by continuous subcutaneous infusion with alzet pump.
- the "GLP- 1 " group of mice receives 3 nmol/kg/day of a GLP- 1 compound through an alzet pump and a daily subcutaneous injection of 0.05mL/10g of PBS.
- the "GLP-I + FGF-21” group of mice receives 3 nmol/kg/day of a GLP-I compound through an alzet pump and a daily subcutaneous injection of 1 mg/kg of a FGF-21 compound. Injections occur prior to the onset of the dark photoperiod. Starting weight values are measured after implantation of alzet pumps on Day 1.
- Data in Table 1 represent results where the FGF-21 compound is human FGF-21 (SEQ ID NO: 1) and where the GLP-I compound is Val ⁇ Glu ⁇ -Ile ⁇ -Gly ⁇ -Pro ⁇ -Ser 38 - Ser ⁇ -Gly ⁇ -Ala ⁇ -Pro ⁇ -Pro ⁇ -Pro ⁇ -Ser ⁇ -GLP-l (SEQ ID NO: 19).
- the data demonstrate that the use of a FGF-21 compound in combination with a GLP-I compound results in a synergistic effect on weight loss.
Abstract
The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention.
Description
TREATMENT FOR OBESITY
The present invention relates to compositions that comprise an FGF-21 compound and a GLP-I compound. These compositions can be used to lower body weight and treat obesity.
BACKGROUND OF THE INVENTION
Obesity, and especially upper body obesity, is the most common nutritional disorder in the over-nourished populations of the world. Current methods for promoting weight loss are not completely satisfactory. Unfortunately, an estimated 33 billion dollars a year are spent on weight-loss measures that are largely futile. Thus, new methods and compositions such as pharmaceutical agents that promote weight-loss are urgently needed to complement old approaches. Fibroblast growth factor 21 (FGF-21) belongs to a family of large polypeptides widely expressed in developing and adult tissues that play crucial roles in multiple physiological functions. FGF-21 has been reported to stimulate glucose-uptake in mouse adipocytes after prolonged treatment, in the presence and absence of insulin, and to decrease fed and fasting blood glucose, triglycerides, and glucagon levels in ob/ob and db/db mice in a dose-dependent manner, thus, providing the basis for the use of FGF-21 as a therapy for treating diabetes and obesity (WO03/011213).
In addition to its beneficial effects on Type 2 diabetes, Glucagon-like peptide- 1 (GLP-I) compounds have been described for the treatment of obesity. (WO98/019698). Although both FGF-21 and GLP-I compounds have shown positive effects in treating obesity, there has not been any indication that a combination of FGF-21 compounds and GLP-I compounds would provide a synergistic effect on lowering body weight. There is thus, still a need for additional beneficial therapeutics for weight loss.
Applicants have determined that a combination of an FGF-21 compound and a GLP-I compound have an unexpected synergistic effect on lowering body weight.
SUMMARY OF THE INVENTION
The present invention relates to compositions comprising a FGF-21 compound and a GLP-I compound. The present invention also provides a method of lowering body weight comprising administering an FGF-21 compound in combination with a GLP-I compound. In another embodiment, the present invention provides a method of treating obesity comprising administering a FGF-21 compound in combination with a GLP-I compound.
The present invention also provides compositions comprising a FGF-21 compound and an exendin compound. The present invention also provides a method of lowering body weight comprising administering an FGF-21 compound in combination with an exendin compound. In another embodiment, the present invention provides a method of treating obesity comprising administering a FGF-21 compound in combination with an exendin compound.
DETAILED DESCRIPTION
A "FGF-21 compound" is defined as a compound comprising native human FGF- 21 (SEQ ID NO: 2), an FGF-21 analog, or an FGF-21 derivative. The FGF-21 compounds of the present invention retain FGF-21 activity as measured in assays as described in Kharitonenkov, et α/.,(Journal of Clinical Investigation, 115(6): 1627 (2005)). A "FGF-21 analog" is defined as a molecule having a modification including one or more amino acid substitutions, deletions, inversions or additions when compared with SEQ ID NO: 2.
A "FGF-21 derivative" is defined as a molecule having the amino acid sequence of human FGF-21 (SEQ ID NO : 2) or of a FGF-21 analog but additionally having at least one chemical modification of one or more of its amino acid side groups, α -carbon atoms, terminal amino group, or terminal carboxylic acid group. Modifications at amino acid side groups include acylation of lysine e-amino groups, N-alkylation of arginine, histidine, or lysine, alkylation of glutamic or aspartic carboxylic acid groups, and deamidation of glutamine or asparagine. Modifications of the terminal amino include the des-amino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications. Modifications of
the terminal carboxy group include the amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications. A lower alkyl is a C i-C 4alkyl. Furthermore, one or more side groups, or terminal groups, may be protected by protective groups known to the ordinarily-skilled protein chemist. The α-carbon of an amino acid may be mono-or di- methylated. The chemical modification may also include "pegylation."
Specific substitutions to human FGF-21, FGF-21 analog or FGF-21 derivative indicated using the specific amino acid present after substitution or modification at a particular residue followed by the residue number. For example, Cys118-FGF-21 indicates that there has been a cysteine introduced at position 118 of human FGF-21. A "GLP-I compound" is defined as a compound comprising the amino acid sequence of native human GLP-I (SEQ ID NO: 3), a GLP-I analog or GLP-I derivative, which maintains GLP-I activity. GLP-I activity may be measured by methods known in the art, including using in vivo experiments and in vitro assays that measure GLP-I receptor binding activity or receptor activation, e.g., assays employing pancreatic islet cells or insulinoma cells, as described in EP 619,322, Gelfand, et ai, and U.S. Patent No. 5,120,712, respectively. GLP-I compounds are well known in the art. See, e.g. PCT International Application Publication Nos. WO 03/040309, U.S. patent Nos. 6,593,295, 7,141,547, and 7,176,278.
A "GLP-I analog" is defined as a molecule having a modification including one or more amino acid substitutions, deletions, inversions, or additions when compared with SEQ ID NO: 3. "GLP-I analog" also includes "GLP-I fusion proteins" where the GLP-I fusion protein is a heterologous protein comprising a GLP-I or GLP-I analog and a second polypeptide selected from the group consisting of human albumin, human albumin analogs, fragments of human albumin, transferrin, transferrin analogs, transferrin derivatives, fragments of transferring, the Fc portion of an immunoglobulin, an analog of the Fc portion of an immunoglobulin, and fragments of the Fc portion of an immunoglobulin, and wherein the C-terminus of the first polypeptide is fused to the N- terminus of the second polypeptide. The GLP-I or GLP-I analog may be fused to the second polypeptide via a peptide linker. The GLP-I fusion proteins of the present invention contain an Fc portion which is derived from human IgG4 but comprises one or more substitutions compared to the wild-type human sequence (SEQ ID NO: 5).
A "GLP-I derivative" is defined as a molecule having the amino acid sequence of native human GLP-I or of a GLP-I analog, but additionally having at least one chemical modification of one or more of its amino acid side groups, a-carbon atoms, terminal amino group, or terminal carboxylic acid group. Modifications at amino acid side groups include acylation of lysine e-amino groups, N-alkylation of arginine, histidine, or lysine, alkylation of glutamic or aspartic carboxylic acid groups, and deamidation of glutamine or asparagine. Modifications of the terminal amino include the des-amino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications. Modifications of the terminal carboxy group include the amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications. A lower alkyl is a C \-C 4alkyl. Furthermore, one or more side groups, or terminal groups, may be protected by protective groups known to the ordinarily-skilled protein chemist. The α-carbon ofan amino acid may be mono-or di-methylated. The chemical modification may also include the pegylation of an amino acid of the peptide or polypeptide. The nomenclature used herein to refer to specific GLP-I analogs and GLP-I derivatives is defined as follows: Specific substitutions to a GLP-I analog and GLP-I derivative are indicated using the specific amino acid being substituted followed by the residue number. GLP-l(7-37) indicates that the GLP-I analog portion of the mature fusion protein begins with His at position 7 and ends with Gly at position 37. In the case of additions of amino acids to a GLP-I amino acid sequence, the added amino acid is indicated followed by the position at which it is present. For example, the addition of two serine residues to the C-terminus of wild type GLP-I will be referred to as Ser^-Ser39- GLP-I.
An "exendin compound" is defined as a compound comprising the amino acid sequence of exendin-4 (SEQ ID NO: 4), an exendin-4 analog or exendin-4 derivative, wherein the exendin compound maintains exendin-4 activity.
An "exendin-4 analog" is defined as a compound having a modification including one or more amino acid substitutions, deletions, inversions, or additions when compared with the amino acid sequence of exendin-4 (SEQ ID NO: 4). "Exendin-4 analog" also includes "exendin fusion proteins" where the "exendin fusion protein" is a heterologous protein comprising an exendin-4 or exendin-4 analog and a second polypeptide selected
from the group consisting of human albumin, human albumin analogs, fragments of human albumin, transferrin, transferrin analogs, transferrin derivatives, fragments of transferring, the Fc portion of an immunoglobulin, an analog of the Fc portion of an immunoglobulin, and fragments of the Fc portion of an immunoglobulin, and wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide. The exendin-4 or exendin-4 analog may be fused to the second polypeptide via a peptide linker. The exendin-4 fusion proteins of the present invention may contain an Fc portion which is derived from human IgG4 but comprises one or more substitutions compared to the wild-type human sequence (SEQ ID NO: 5). An "exendin-4 derivative" is defined as a compound having the amino acid sequence of exendin-4 or of an exendin-4 analog, but additionally having at least one chemical modification of one or more of its amino acid side groups, a-carbon atoms, terminal amino group, or terminal carboxylic acid group. Modifications at amino acid side groups include acylation of lysine e-amino groups, N-alkylation of arginine, histidine, or lysine, alkylation of glutamic or aspartic carboxylic acid groups, and deamidation of glutamine or asparagine. Modifications of the terminal amino include the des-amino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications. Modifications of the terminal carboxy group include the amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications. A lower alkyl is a C i-C 4alkyl. Furthermore, one or more side groups, or terminal groups, may be protected by protective groups known to the ordinarily-skilled protein chemist. The α-carbon of an amino acid may be mono-or di- methylated. The chemical modification may also include pegylation.
As used herein, the Fc portion of an immunoglobulin has the meaning commonly given to the term in the field of immunology. Specifically, this term refers to an antibody fragment which does not contain the two antigen binding regions (the Fab fragments) from the antibody. The Fc portion consists of the constant region of an antibody from both heavy chains, which associate through non-covalent interactions and disulfide bonds. The Fc portion can include the hinge regions and extend through the CH2 and CH3 domains to the c-terminus of the antibody. The Fc portion can further include one or more glycosylation sites.
The fusion proteins described herein may also contain a linker ("L"). The linker may comprise the sequence Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly- Gly-Ser (SEQ ID NO: 6). The number immediately preceding the L refers to the number of linkers separating the particular peptide or protein portion from the Fc portion. A linker specified as 1.5L refers to the sequence Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly- Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 7). IgG4 refers to an analog of the human IgG4 Fc sequence specified as SEQ ID NO: 5. Substitutions in the IgG4 Fc portion of the fusion protein are indicated in parenthesis. The wild-type amino acid is specified by its common abbreviation followed by the position number in the context of the entire IgG4 sequence using the EU numbering system followed by the amino acid being substituted at that position specified by its common abbreviation.
"Pegylation" or "Pegylated" refers to a compound of the present invention that is chemically modified by covalent attachment of a molecule or molecules of polyethylene glycol or a derivative thereof. Furthermore, it is intended that the term "PEG" refers to polyethylene glycol or a derivative thereof as are known in the art. In its typical form, PEG is a linear polymer with terminal hydroxyl groups and has the formula HO-CH2CH2- (CH2CH2O)W-CH2CH2-OH, where n is from about 8 to about 4000. The terminal hydrogen may be substituted with a protective group such as an alkyl or aryl group. Preferably, PEG has at least one hydroxy group, more preferably it is a terminal hydroxy group. It is this hydroxy group which is preferably activated to react with the peptide. There are many forms of PEG useful for the present invention. Numerous derivatives of PEG exist in the art and are suitable for use in the invention. The PEG molecule covalently attached to compounds in the present invention is not intended to be limited to a particular type. PEG'S molecular weight is preferably from 500-100,000 daltons and more preferably from 20,000-60,000 daltons and most preferably from 20,000-40,000 daltons. PEG may be linear or branched.
"In combination with" or "coadministration" refers to the administration of a FGF- 21 compound with a GLP-I compound either simultaneously, sequentially or a combination thereof. The combination therapy of a FGF-21 compound with a GLP-I compound results in a synergistic effect in lowering body weight and thus, in the
treatment of obesity. The combination therapy also results in a synergistic effect on lower elevated blood glucose levels and thus, a potential use in the treatment of diabetes.
The term "synergy" or "synergistic" as used herein is defined to mean a combination of components wherein the effect of the combination is greater than the additive individual effects of each component of the combination. For purposes of the present invention, "effect" refers to a loss in body weight, lowering of body weight or a reduction in blood glucose levels.
The FGF-21 compounds, the GLP-I compounds and the exendin compounds of the present invention may be made using various techniques known to one of skill in the art. For example, the FGF-21, GLP-I and exendin compounds may be made using recombinant techniques. As the DNA sequences of mature human FGF-21 (SEQ ID NO: 1), native GLP-I, and exendin-4 are known, PCR methodology may be used to isolate genes encoding the corresponding gene. Further, one of skill in the art is aware of various methods to introduce changes in the DNA sequence so as to effect desired changes in the amino acid sequence of the resulting FGF-21 , GLP- 1 or exendin compounds.
The GLP-I and the exendin peptides of the present invention can also be prepared by using standard methods of solid-phase peptide synthesis techniques. Peptide synthesizers are commercially available from, for example, Applied Biosystems in Foster City, Calif. Reagents for solid phase synthesis are commercially available, for example, from Midwest Biotech (Fishers, Ind ). Solid phase peptide synthesizers can be used according to manufacturer's instructions for blocking interfering groups, protecting the amino acid to be reacted, coupling, decoupling, and capping of unreacted amino acids. A wide variety of methods have been described in the art to covalently conjugate PEGs to peptides (for review article see, Roberts, M. et al. Advanced Drug Delivery Reviews, 54:459-476, 2002). Pegylation of peptides at the carboxy-terminus may be performed via enzymatic coupling using recombinant compounds of the present invention as a precursor or alternative methods known in the art and described. See e.g. U.S. Patent 4,343,898 or InternationalJσurnal of Peptide & Protein Research.43A27-38, 1994. Various methods of protein purification may be employed and such methods are known in the art and described, for example, in Deutscher, Methods in Enzymology 182:
83-9 (1990) and Scopes, Protein Purification: Principles and Practice, Springer- Verlag, NY (1982). The purification step(s) selected will depend on the nature of the production process used and the particular protein produced. For example, fusion proteins comprising an Fc fragment can be effectively purified using a Protein A or Protein G affinity matrix. Low or high pH buffers can be used to elute the fusion protein from the affinity matrix. Mild elution conditions will aid in preventing irreversible denaturation of the fusion protein.
Coadministration of FGF-21 compounds, GLP-I compounds and exendin compounds of the present invention may be via any route known to be effective by the physician of ordinary skill. Peripheral parenteral is one such method. Parenteral administration is commonly understood in the medical literature as the injection of a dosage form into the body by a sterile syringe or some other mechanical device such as an infusion pump. Peripheral parenteral routes can include intravenous, intramuscular, subcutaneous, and intraperitoneal routes of administration. Those skilled in the art can readily optimize pharmaceutically effective dosages and administration regimens for the combinations of the present invention, as determined by good medical practice and the clinical condition of the individual patient. For example, a typical dose range for the FGF-21 compounds of the present invention will range from about 0.01 mg per day to about 1000 mg per day for an adult. A typical dose range for the GLP-I derivative compounds of the present invention will range from about 0.01 mg per day to about 1000 mg per day for an adult. For GLP-I fusion proteins, doses may be in the range of 0.01 to 1 mg/kg body weight, preferably in the range of 0.05 to 0.5 mg/kg body weight.
In an embodiment, the present invention provides a composition comprising a FGF-21 compound and a GLP-I compound. In another embodiment, the present invention provides a composition comprising a FGF-21 compound and a GLP-I compound, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the GLP-I compound is selected from the group consisting of GLP-I analog, GLP-I derivative and GLP-I fusion proteins. In a preferred embodiment, the composition comprises an FGF- 21 analog and a GLP-I analog. In another preferred embodiment, the composition
comprises a FGF-21 analog and a GLP-I derivative. In another preferred embodiment, the composition comprises a FGF-21 analog and a GLP-I fusion protein.
In another embodiment, the present invention provides a composition comprising an FGF-21 compound and an exendin compound. In a preferred embodiment, the composition comprises a FGF-21 compound and an exendin compound, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the exendin compound is selected from the group consisting of exendin-4, an exendin-4 analog, an exendin-4 derivative, and an exendin-4 agonist. In a preferred embodiment, the composition comprises a FGF-21 analog and exendin-4. In another preferred embodiment, the composition comprises a FGF-21 analog and an exendin-4 analog. In another preferred embodiment, the composition comprises a FGF-21 analog and an exendin-4 derivative. In another preferred embodiment, the composition comprises a FGF-21 analog and an exendin-4 agonist. The present invention also provides a method of lowering body weight comprising administering a FGF-21 compound in combination with a GLP-I compound. In a more preferred embodiment, administering a FGF-21 compound in combination with a GLP-I compound results in a synergistic effect on weight loss. In another embodiment, the method of lowering body weight comprises administering a FGF-21 compound in combination with a GLP-I compound, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the GLP-I compound is selected from the group consisting of GLP-I analog, GLP-I derivative and GLP-I fusion protein. In a preferred embodiment, the method of lowering body weight comprises administering a FGF-21 analog in combination with a GLP-I analog. In another preferred embodiment, the method of lowering body weight comprises administering a FGF-21 analog in combination with a GLP-I derivative. In another preferred embodiment, the method of lowering body weight comprises administering a FGF-21 analog and a GLP-I fusion protein.
The present invention also provides a method of lowering body weight comprising administering a FGF-21 compound in combination with an exendin compound. In more preferred embodiment, administering a FGF-21 compound in combination with an
exendin compound results in a synergistic effect on weight loss. In an embodiment, the method of lowering body weight comprises administering a FGF-21 compound in combination with an exendin compound, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the exendin compound is selected from the group consisting of exendin-4, an exendin-4 analog, an exendin-4 derivative, and an exendin-4 agonist. In a preferred embodiment, the method of lowering body weight comprises administering a FGF-21 analog in combination with exendin-4. In another preferred embodiment, the method of lowering body weight comprises administering a FGF-21 analog in combination with an exendin-4 analog. In another preferred embodiment, the method of lowering body weight comprises administering a FGF-21 analog and an exendin-4 derivative. In another preferred embodiment, the method of lowering body weight comprises administering a FGF-21 analog and an exendin-4 agonist.
The present invention also provides a method of treating obesity comprising administering a FGF-21 compound in combination with a GLP-I compound. In more preferred embodiment, administering a FGF-21 compound in combination with a GLP-I compound results in a synergistic effect on weight loss. In an embodiment, the method of treating obesity comprises administering a FGF-21 compound in combination with a GLP-I compound, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the GLP-I compound is selected from the group consisting of GLP-I analog, GLP-I derivative and GLP-I fusion protein. In a preferred embodiment, the method of treating obesity comprises administering a FGF-21 analog in combination with a GLP-I analog. In another preferred embodiment, the method of treating obesity comprises administering a FGF-21 analog in combination with a GLP-I derivative. In another preferred embodiment, the method of treating obesity comprises administering a FGF-21 analog and a GLP-I fusion protein.
The present invention also provides a method of treating obesity comprising administering a FGF-21 compound in combination with an exendin compound. In more preferred embodiment, administering a FGF-21 compound in combination with an exendin compound results in a synergistic effect on weight loss. In an embodiment, the
method of treating obesity comprises administering a FGF-21 compound in combination with an exendin compound, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the exendin compound is selected from the group consisting of exendin-4, an exendin-4 analog, an exendin-4 derivative, and exendin-4 agonist. In a preferred embodiment, the method of treating obesity comprises administering a FGF-21 analog in combination with exendin-4. In another preferred embodiment, the method of treating obesity comprises administering a FGF-21 analog in combination with an exendin-4 analog. In another preferred embodiment, the method of treating obesity comprises administering a FGF-21 analog and an exendin-4 derivative. In another preferred embodiment, the method of treating obesity comprises administering a FGF-21 analog and an exendin-4 agonist. The present invention also provides for the use of a FGF-21 compound and a GLP-I compound in the manufacture of a medicament to lower body weight. The present invention also provides for the use of a FGF-21 compound and a GLP-I compound in the manufacture of a medicament to lower body weight, wherein the FGF-21 compound i s selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the GLP-I compound is selected from the group consisting of a GLP-I analog, a GLP-I derivative and a GLP-I fusion protein. In a preferred embodiment, the present invention provides for the use of a FGF-21 analog and a GLP-I analog in the manufacture of a medicament to lower body weight. In another preferred embodiment, the present invention provides for the use of a FGF-21 analog and a GLP-I derivative in the manufacture of a medicament to lower body weight. In another preferred embodiment, the present invention provides for the use of a FGF-21 analog and a GLP-I fusion protein in the manufacture of a medicament to lower body weight. The present invention also provides for the use of a FGF-21 compound and an exendin compound in the manufacture of a medicament to lower body weight. The present invention also provides for the use of a FGF-21 compound and an exendin compound in the manufacture of a medicament to lower body weight, wherein the FGF- 21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the exendin compound is selected from the group consisting of exendin-4, an exendin-4 analog, an exendin-4 derivative, and an exendin-4
agonist.. In a preferred embodiment, the present invention provides for the use of a FGF- 21 analog and an exendin-4 analog in the manufacture of a medicament to lower body weight. In another preferred embodiment, the present invention provides for the use of a FGF-21 analog and an exendin-4 derivative in the manufacture of a medicament to lower body weight. In another preferred embodiment, the present invention provides for the use of a FGF-21 analog and an exendin-4 agonist in the manufacture of a medicament to lower body weight.
The present invention also provides for the use of a FGF-21 compound and a GLP-I compound in the manufacture of a medicament for the treatment of obesity. The present invention also provides for the use of a FGF-21 compound and a GLP- 1 compound in the manufacture of a medicament for the treatment of obesity, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF-21 derivative and wherein the GLP-I compound is selected from the group consisting of a GLP-I analog, a GLP-I derivative and a GLP-I fusion protein. In a preferred embodiment, the present invention provides for the use of a FGF-21 analog and a GLP-I analog in the manufacture of a medicament for the treatment of obesity. In another preferred embodiment, the present invention provides for the use of a FGF-21 analog and a GLP-I derivative in the manufacture of a medicament for the treatment of obesity. In another preferred embodiment, the present invention provides for the use of a FGF-21 analog and a GLP-I fusion protein in the manufacture of a medicament for the treatment of obesity.
The present invention also provides for the use of a FGF-21 compound and an exendin compound in the manufacture of a medicament to treat obesity. The present invention also provides for the use of a FGF-21 compound and an exendin compound in the manufacture of a medicament to lower body weight, wherein the FGF-21 compound is selected from the group consisting of human FGF-21, an FGF-21 analog and an FGF- 21 derivative and wherein the exendin compound is selected from the group consisting of exendin-4, an exendin-4 analog, an exendin-4 derivative, and an exendin-4 agonist. In a preferred embodiment, the present invention provides for the use of a FGF-21 analog and an exendin-4 analog in the manufacture of a medicament to treat obesity. In another preferred embodiment, the present invention provides for the use of a FGF-21 analog and
an exendin-4 derivative in the manufacture of a medicament to treat obesity. In another preferred embodiment, the present invention provides for the use of a FGF-21 analog and an exendin-4 agonist in the manufacture of a medicament to treat obesity.
The FGF-21 compounds of the present invention may be human FGF-21, a FGF- 21 analog or a FGF-21 derivative. In a preferred embodiment, the FGF-21 compound of the present invention is a FGF-21 analog. In a more preferred embodiment, the present invention provides FGF-21 compounds comprising one or two engineered disulfide bonds. In a more preferred embodiment, the present invention provides FGF-21 compounds which comprise an amino acid sequence comprising a cysteine substitution at positions 21, 26, 33, 118, 119, 121, 122, or 134 of FGF-21 (SEQ ID NO: 2). In another preferred embodiment, the FGF-21 compound comprises an amino acid sequence comprising an amino acid substitution at position 167 of FGF-21 (SEQ ID NO: 2), wherein the substitution is not Ser or Tyr. In another preferred embodiment, the FGF-21 compound comprises an amino acid sequence comprising an amino acid substitution at position 121 of FGF-21 (SEQ ID NO: 2), wherein the substitution is any amino acid except Gln or Asn. In a more preferred embodiment, the amino acid at position 121 of FGF-21 (SEQ ID NO: 2) is selected from the group consisting of Ala, VaI, Ser, Asp, or Glu. In a more preferred embodiment, the FGF-21 compound comprises an amino acid sequence selected from the group consisting of Cysm-Cys134-FGF-21 (SEQ ID NO: 9), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10), Cys21-Cys33-Ala167-FGF-21 (SEQ ID NO: 11), Cys26-Cysm-Ala167- FGF-21 (SEQ ID NO: 12), and CysM8-Cys134-Ala121- Ala167-FGF-21 (SEQ ID NO: 13). In a more preferred embodiment, the FGF-21 compound consists of an amino acid sequence selected from the group consisting of Cys118-Cys134-FGF-21 (SEQ ID NO: 9), Cys118-Cys134-Ala167-FGF-21 (SEQ ED NO: 10), Cys21-Cys33-Ala167-FGF-21 (SEQ ID NO: 11), Cys26-Cys122-Ala167- FGF-21 (SEQ ID NO: 12), and Cys118-Cys134-Ala121-AlaI67-FGF-21 (SEQ DD NO: 13).
In an embodiment, the present invention provides FGF-21 compounds which consist of a cysteine substitution at positions 21, 26, 33, 118, 119, 121, 122, or 134 of FGF-21 (SEQ ID NO: 2). In another embodiment, the FGF-21 compound consist of an amino acid substitution at position 167 of FGF-21 (SEQ ID NO: 2), wherein the substitution is not Ser or Tyr. In another preferred embodiment, the FGF-21 compound
consists of a substitution at position 121 of FGF-21 (SEQ ID NO: 2), wherein the substitution is any amino acid except Gln or Asn. In a more preferred embodiment, the amino acid at position 121 of FGF-21 (SEQ ID NO: 2) is selected from the group consisting of Ala, VaI, Ser, Asp, or Glu. In a more preferred embodiment, the FGF-21 compound consists of an amino acid sequence selected from the group consisting of Cys118-Cys134-FGF-21 (SEQ ID NO: 9), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10), Cys21-Cys33-Ala167-FGF-21 (SEQ ID NO: 11), Cys26-Cys122-Ala167- FGF-21 (SEQ ID NO: 12), and Cys118-Cys134-Ala12I-Ala167-FGF-21 (SEQ ID NO: 13).
Further, the present invention provides GLP-I compounds to be used in combination with the FGF-21 compounds of the present invention. In an embodiment, the GLP-I compound is a GLP-I analog, GLP-I derivative, or a GLP-I fusion protein. In a more preferred embodiment, the GLP-I compound is a GLP-I analog or derivative. In a preferred embodiment, the GLP-I compound is a GLP-I analog. In a more preferred embodiment, the GLP-I compound comprises of an amino acid sequence of SEQ ID NO: 14
His Xaa Glu Gly Thr Phe Thr Ser Asp VaI Ser Ser
10 15
Tyr Leu Glu Xaa Gln Ala Ala Lys Glu Phe lie Ala 20 25 30
Trp Leu Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40
Xaa Xaa Xaa
45
wherein
Xaa at position 8 is Gly, Ala, VaI, Xaa at position 22 is Gly, Glu, Asp, or Lys, Xaa at position 33 is VaI, or He, Xaa at position 34 is Lys or Arg, Xaa at position 36 is Arg or Gly,
Xaa at position 37 is selected from the group consisting of NH2, Gly and Pro, Xaa at position 38 is Ser or absent, Xaa at position 39 is Ser or absent, Xaa at position 40 is Gly or absent, Xaa at position 41 is Ala or absent, Xaa at position 42 is Pro or absent, Xaa at position 43 is Pro or absent, Xaa at position 44 is Pro or absent, and Xaa at position 45 is Ser or absent.
In an embodiment, the GLP-I compound comprises Ala at Xaa8. In another embodiment, the GLP-I compound comprises VaI at Xaag. In another embodiment, the GLP-I compound comprises Gly at Xaa22. In a preferred embodiment, the GLP-I compound comprises Gly at Xaa22- In a preferred embodiment, the GLP-I compound comprises Lys at Xaa34. In another preferred embodiment, the GLP-I compound comprises Arg at Xaa34. In a more preferred embodiment, the amino acid sequence of the GLP-I analog comprises Val8-Glu22-πe33-Gly^-Pro^-Se^-Sei^'-Gly^-Ala^-Pro^-Pro^-Pro^-Ser45- GLP-I (SEQ ID NO: 19). In another embodiment, the amino acid sequence of the GLP-I analog consists of Val^Glu^-Ue^-Gly^-Pro^-Se^^Se^-Gly^-Ala^-Pro^-Pro^-Pro44- Ser45-GLP-1 (SEQ ID NO: 19).
In a preferred embodiment, the amino acid sequence of the GLP-I compound comprises Val8-GLP-1 (SEQ ED NO: 15). In a preferred embodiment, the amino acid sequence of the GLP-I compound consists of the amino acid sequence Val8-GLP-1 (SEQ ID NO: 15). In another preferred embodiment, the amino acid sequence of the GLP-I compound comprises Arg^-GLP-l (SEQ ID NO: 16). In another preferred embodiment, the amino acid sequence of the GLP-I compound consists of Arg34-GLP-1 (SEQ ED NO: 16). In another preferred embodiment, the amino acid sequence of the GLP-I compound comprises Val8-Glu22-GLP-1 (SEQ ED NO: 17). In another preferred embodiment, the amino acid sequence of the GLP-I compound consists of Val8-Glu22-GLP-1 (SEQ ED NO: 17). In another preferred embodiment, the amino acid sequence of VaI8-Glu22-GLP- 1 (SEQ ED NO: 17) comprises of five additional amino acid sequence substitutions. In
16
another preferred embodiment, the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) consists of five additional amino acid sequence substitutions. In another preferred embodiment, the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) comprises of four additional amino acid sequence substitutions. In another preferred embodiment, the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) consists of four additional amino acid sequence substitutions. In another preferred embodiment, the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) comprises of three additional amino acid sequence substitutions. In another preferred embodiment, the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) consists of three additional amino acid sequence substitutions. In another preferred embodiment, the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) comprises of two additional amino acid sequence substitutions. In another preferred embodiment, the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) consists of two additional amino acid sequence substitutions. In another preferred embodiment, the amino acid sequence of Val8-Glu22- GLP-I (SEQ ID NO: 17) comprises of one additional amino acid sequence substitution. In another preferred embodiment, the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) consists of one additional amino acid sequence substitution.
The present invention also provides GLP-I derivatives in combination with FGF- 21 compounds. In another preferred embodiment, the GLP-I derivative is pegylated. In a preferred embodiment, the GLP-I derivative comprises of an amino acid sequence of SEQ ID NO: 20
His Xaa Glu Gly Thr Phe Thr Ser Asp VaI Ser Ser
10 15
Tyr Leu Glu Xaa Gln Ala Ala Lys Glu Phe lie Ala 20 25 30
Trp Leu Xaa Lys Gly Gly Pro Ser Ser Gly Ala Pro
35 40
Pro Pro Cys Xaa
45 wherein
Xaa at position 8 is: D-Ala, Gly, VaI, Leu, lie, Ser, or Thr;
17
Xaa at position 22 is: Gly, Glu, Asp, or Lys; Xaa at position 33 is: VaI or He Xaa at position 46 is: Cys or CyS-NH2 and wherein one PEG molecule is covalently attached to Cys45 and one PEG molecule is covalently attached to Cys46 or Cys46-NH2. In another embodiment, the GLP-I derivative consists of the amino acid sequence of SEQ ID NO:20.
In an embodiment, Xaag is VaI or Gly. In another embodiment, Xaa22 is Gly or Glu. In another embodiment, Xaa33 is He. In an embodiment, Xaa^ is CyS-NH2. In a preferred embodiment, the GLP-I derivative comprises of the amino acid sequence of Val8-Glu22-Ile33-Cys-NH2 46-GLP- 1 (SEQ ID NO: 21 ). In a preferred embodiment, the GLP-I derivative consists of the amino acid sequence of Val8-Glu22-Ile33-Cys-NH2 4δ- GLP-I (SEQ ID NO: 21).
In another embodiment, the GLP-I compound is a GLP-I fusion protein. In a preferred embodiment, the GLP-I fusion protein comprises a GLP-I portion and an Fc portion of an immunoglobulin. In a preferred embodiment, the GLP-I fusion protein comprises a GLP-I analog and the Fc portion of an immunoglobulin wherein the GLP-I analog comprises an amino acid sequence of SEQ ID NO: 22
His Xaa Glu Gly Thr Phe Thr Ser Asp VaI Ser Ser
10 15 Tyr Leu Glu Glu Gln Ala Ala Lys Glu Phe lie Ala
20 25 30
Trp Leu Xaa Xaa Gly Gly Xaa
35 wherein Xaa at position 8 is Gly or VaI; Xaa at position 33 is VaI or Lys; Xaa at position 34 is Lys or Asn; Xaa at position 37 is Gly, Pro or is absent, and wherein the GLP analog is fused to the Fc portion of an immunoglobulin comprising the amino acid sequence of Formula IV (SEQ ID NO: 23)
Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys
18
5 10
Pro Ala Pro Xaa Xaa Xaa Gly Gly Pro Ser VaI Phe
15 20
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie 25 30 35
Ser Arg Thr Pro Glu VaI Thr Cys VaI VaI VaI Asp
40 45
VaI Ser Gln Glu Asp Pro Glu VaI Gln Phe Asn Trp
50 55 60 Tyr VaI Asp Gly VaI Glu VaI His Asn Ala Lys Thr
65 70
Lys Pro Arg Glu Glu Gln Phe Xaa Ser Thr Tyr Arg
75 80
VaI VaI Ser VaI Leu Thr VaI Leu His Gln Asp Trp 85 90 95
Leu Asn Gly Lys Glu Tyr Lys Cys Lys VaI Ser Asn
100 105
Lys Gly Leu Pro Ser Ser lie Glu Lys Thr lie Ser
110 115 120 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln VaI Tyr
125 130
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
135 140
Gln VaI Ser Leu Thr Cys Leu VaI Lys Gly Phe Tyr 145 150 155
Pro Ser Asp lie Ala VaI Glu Trp Glu Ser Asn Gly
160 165
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro VaI
170 175 180 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
185 190
Leu Thr VaI Asp Lys Ser Arg Trp Gln Glu Gly Asn 195 200
19
VaI Phe Ser Cys Ser VaI Met His Glu Ala Leu His 205 210 215
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
220 225 Gly Xaa 230
wherein:
Xaa at position 16 is Pro or Glu; Xaa at position 17 is Phe, VaI, or Ala; Xaa at position 18 is Leu, Glu, or Ala; Xaa at position 80 is Asn or Ala; and Xaa at position 230 is Lys or is absent.
In a preferred embodiment, the C-terminus of the GLP-I analog and the N- terminus of the Fc portion of an immunoglobulin are preferably fused together via 1, 1.5 (SEQ ID NO: 7) or 2 repeats (SEQ ID NO: 8) of a G-rich peptide linker having the sequence Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 6). In a preferred embodiment, the GLP-I fusion protein comprises a GLP-I analog and the Fc portion of an immunoglobulin wherein the GLP-I analog consists of an amino acid sequence of SEQ BD NO: 22 and wherein the GLP analog is fused to the Fc portion of an immunoglobulin consisting of the amino acid sequence of SEQ ID NO: 23. In another embodiment, the GLP-I fusion protein further comprises a linker. In another embodiment, the GLP-I fusion protein further comprises a linker, wherein the linker comprises an amino acid sequence is selected from the group consisting of SEQ ID NO: 6, SEQ BD NO:7 and SEQ BD NO:8. In another embodiment, the GLP-I fusion protein further comprises a linker, wherein the linker consists of an amino acid sequence is selected from the group consisting of SEQ DD NO: 6, SEQ DD NO:7 and SEQ BD NO:8. In an embodiment, the linker comprises an amino acid sequence of SEQ ED NO:6. In an embodiment, the linker comprises an amino acid sequence of SEQ ID NO:7. In an embodiment, the linker comprises an amino acid sequence of SEQ BD NO: 8. In an
20
embodiment, the linker consists of an amino acid sequence of SEQ ID NO:6. In an embodiment, the linker consists of an amino acid sequence of SEQ ID NO:7. In an embodiment, the linker consists of an amino acid sequence of SEQ ID NO 8
In an embodiment of the present invention, the GLP-I portion comprises Gly at Xaa8. In another embodiment, the GLP-I portion comprises VaI at Xaaβ. In an embodiment, the GLP-I portion comprises Gly at Xaa22- In a preferred embodiment, the GLP-I portion comprises Glu at Xaa22- In an embodiment, the GLP-I portion comprises Ly s at Xaa34. In another embodiment, the GLP-I portion comprises Asn at Xaa34. In an embodiment, Xaa37 of the GLP-I portion is absent. In a preferred embodiment, the GLP- 1 portion comprises Gly at Xaa37. In another preferred embodiment, the GLP-I portion comprises Pro at Xaa37.
Preferred GLP-I fusion proteins of the present invention include the following proteins: Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P) (SEQ ID NO: 24), Gly8-Glu22- Gly36-GLP-1-lL-IgG4 (S228P, F234A, L235A) (SEQ ID NO: 25), Gly8-Glu22-Gly36- GLP-1-lL-IgG4 (S228P, N297A) (SEQ ID NO: 26), Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P, F234A, L235A, N297A) (SEQ ID NO: 27), Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P, des K) (SEQ ID NO: 28), Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P, F234A, L235A, des K) (SEQ ID NO: 29), Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P, N297A,des K) (SEQ ID NO: 30), Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P, F234A, L235A, N297A, des K) (SEQ ID NO: 31), Gly8-Glu22-Gly36-GLP-1-1 5L-IgG4 (S228P) (SEQ ID NO: 32), Gly8-Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, F234A, L235A) (SEQ ID NO: 33), Gly8- Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, N297A) (SEQ ID NO: 34), Gly8-Glu22-Gly36- GLP-1-1.5L-IgG4 (S228P, F234A, L235A, N297A) (SEQ ID NO: 35), Gly8-Glu22-Gly36- GLP-1-1.5L-IgG4 (S228P, des K) (SEQ ED NO: 36), Gly8-Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, F234A, L235A, des K) (SEQ ID NO: 37), Gly8-Glu22-Gly36-GLP-1-1 5L-IgG4 (S228P, N297A des K) (SEQ ID NO: 38), Gly8-Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, F234A, L235A, N297A, des K) (SEQ ID NO: 39), Gly8-Glu22-Gly36-GLP-1-2L-IgG4 (S228P) (SEQ ID NO: 40), Gly8-Glu22-Gly36-GLP-1-2L-IgG4 (S228P, F234A, L235A) (SEQ ID NO: 41), Gly8-Glu22-Gly36-GLP-1-2L-IgG4 (S228P, N297A) (SEQ ID NO: 42), Gly8-Glu22-Gly36-GLP-1 -2L-IgG4 (S228P, F234A, L235 A, N297A) (SEQ ID NO: 43), Gly8-Glu22-Gly36-GLP-1-2L-IgG4 (S228P, des K) (SEQ ID NO: 44), Gly8-Glu22-Gly36-
21
GLP-1-2L-IgG4 (S228P, F234A, L235A, des K) (SEQ ID NO: 45), Gly8-Glu22-Gly36- GLP-1-2L-IgG4 (S228P, N297A, des K) (SEQ ID NO: 46), Gly8-Glu22-Gly36-GLP-1-2L- IgG4 (S228P, F234A, L235A, N297A, des K) (SEQ ID NO: 47), and the VaI8 forms of all of the above. The present invention also includes FGF-21 compounds in combination with
GLP-I compounds, wherein the GLP-I compound comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. The present invention also includes FGF-21 compounds in combination with GLP-I compounds, wherein the GLP-I compound consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. Preferred FGF-21 compound and GLP-I compound combinations of the present invention include, Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with VaI8- GLP-I (SEQ ID NO: 15), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Val8-Glu22-GLP-1 (SEQ ID NO: 17), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with is Val8-Glu22-Ile33-Gly36-Pro37-Ser38-Ser39-Gly40-Ala41-Pro42-Pro43- Pro^-Ser^-GLP-KSEQ ID NO: 19), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with pegylated Val8-Glu22-Ile33-Cys-NH2 46-GLP-1 (SEQ ID NO: 21), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Arg34-GLP-1 (SEQ ID NO: 16), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with acylated Arg34-GLP-1 (SEQ ID NO: 16), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Arg34- Lys26-(N-ε -(γ-Glu (N-α-hexadecanoyl)))-GLP-l (SEQ ID NO: 18), Cys118-Cys134-FGF- 21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P) (SEQ ID NO: 24), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22- Gly36-GLP-1-lL-IgG4 (S228P, F234A, L235A) (SEQ ID NO: 25), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P, N297A) (SEQ ED NO: 26), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-
Glu22-Gly36-GLP-1-lL-IgG4 (S228P, F234A, L235A, N297A) (SEQ ID NO: 27), Cys118-
22
Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP-1 -IL-Ig(M (S228P, des K) (SEQ ID NO: 28), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P, F234A, L235A, des K) (SEQ ID NO: 29), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP- l-lL-IgG4 (S228P, N297A, des K) (SEQ ID NO: 30), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P, F234A, L235A, N297A, des K) (SEQ ID NO: 31), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P) (SEQ ID NO: 32), Cys118-Cys134-FGF- 21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, F234A, L235A) (SEQ ID NO: 33), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-GlyM-GLP-1-1.5L-IgG4 (S228P, N297A) (SEQ ID NO: 34), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP- l-1.5L-IgG4 (S228P, F234A, L235A, N297A) (SEQ ID NO: 35), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, des K) (SEQ ID NO: 36), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-
Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, F234A, L235A, des K) (SEQ ID NO: 37), Cys118- Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, N297A, des K) (SEQ ID NO: 38), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, F234A, L235A, N297A, des K) (SEQ ID NO: 39), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP-1-2L-IgG4 (S228P) (SEQ ID NO: 40), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP-1-2L-IgG4 (S228P, F234A, L235A) (SEQ ID NO: 41), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP-1-2L-IgG4 (S228P, N297A) (SEQ ID NO: 42), Cysll8-Cys134- FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly3*-GLP-1-2L-IgG4 (S228P, F234A, L235A, N297A) (SEQ ID NO: 43), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly3<5-GLP-1-2L-IgG4 (S228P, des K) (SEQ ID NO: 44), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP-1-2L- IgG4 (S228P, F234A, L235A, des K) (SEQ ID NO: 45), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-Glu22-Gly36-GLP- 1 -2L-IgG4 (S228P, N297A, des K) (SEQ ID NO: 46), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with Gly8-
23
Glu22-Gly36-GLP-1-2L-IgG4 (S228P, F234A, L235A, N297A, des K) (SEQ ID NO: 47), Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with exendin-4 (SEQ ID NO: 4), Cysm-Cys134-FGF-21 (SEQ K) NO: 9) in combination with albiglutide (SEQ ID NO: 48). Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 47, Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 47, Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 48, Cys118-Cys134-FGF- 21 (SEQ ID NO: 9) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 48, Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 49, Cys118- Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 49, Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 50, Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 50, Cys118-Cysl34-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 51, Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 51, Cys118-Cys134-FGF- 21 (SEQ ID NO: 9) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 52, Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 52, Cys118- Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound comprising the amino acid sequence of SEQ DD NO: 53, Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP- 1 compound consisting of the amino acid sequence of SEQ ID NO: 53, Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 54, Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 54, Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 55, Cys118-Cys134-FGF- 21 (SEQ ID NO: 9) in combination with a GLP-I compound consisting of the amino acid
24
sequence of SEQ ID NO: 55, Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 56, Cys118- Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ED NO: 56, Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 57, and Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 57
In a preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118-Cys!34-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with five additional amino acid sequence substitutions. In a preferred embodiment, the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys118- Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with five additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val8-Glu22- GLP-I (SEQ ID NO: 17) with four additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys118-Cys134-FGF-21 (SEQ ED NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with four additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with three additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in
25
combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with three additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118- Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with two additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of VaI8- Glu22-GLP-1 (SEQ ID NO: 17) with two additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with one additional amino acid sequence substitution. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys118-Cys134-FGF-21 (SEQ ID NO: 9) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with one additional amino acid sequence substitution.
More preferred FGF-21 compound and GLP-I compound combinations of the present invention include Cys1 I8-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with Val8-GLP-1 (SEQ ID NO: 17), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with Vaf-Glu^-GLP-l (SEQ DD NO: 17), Cys118-Cysl34-Ala167-FGF-21 (SEQ ID NO: 10) in combination with is Val8-Glu22-Ile33-Gly36-Pro37-Ser38-Ser39-Gly40- Ala41-Pro42-Pro43-Pro44-Ser45-GLP-1(SEQ DD NO: 19), Cys1I8-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with pegylated Val8-Glu22-Ile33-Cys-NH2 46-GLP-1 (SEQ ID NO: 21), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with Arg34-GLP-1 (SEQ ID NO: 16), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with acylated Arg34-GLP- 1 (SEQ ID NO: 16), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with Arg^-Ly S^-(N-B -(γ-Glu (N-α-hexadecanoyl)))-
26
GLP-I (SEQ ID NO: 18), Cysm-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with Gly8-Glu22-Gly36-GLP-l(7-37)-lL-IgG4 (S228P) (SEQ ID NO: 24), Cys118-Cys134- Ala167-FGF-21 (SEQ ID NO: 10) in combination with Gly8-Glu22-Gly36-GLP-l(7-37)-lL- IgG4 (S228P, F234A, L235A) (SEQ ED NO: 25), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with Gly8-Glu22-Gly36-GLP-l(7-37)-lL-IgG4 (S228P, N297A) (SEQ ID NO: 26), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO:10) in combination with Gly8-Glu22-Gly36-GLP-l(7-37)-lL-IgG4 (S228P, F234A, L235A, N297A) (SEQ DD NO: 27), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with Gly8-Glu22- Gly36-GLP-l(7-37>lL-IgG4 (S228P, des K) (SEQ ID NO: 28), Cys118-CysI34-Ala167- FGF-21 (SEQ ID NO: 10) in combination with Gly8-Glu22-Gly36-GLP-l(7-37)-lL-IgG4 (S228P, F234A, L235A, des K) (SEQ DD NO: 29), Cys118-Cys134-Ala167-FGF-21 (SEQ DD NO: 10) in combination with Gly8-Glu22-Gly36-GLP-l(7-37)-lL-IgG4 (S228P, N297A, des K) (SEQ DD NO: 30), Cys118-Cys134-Ala167-FGF-21 (SEQ DD NO:10) in combination with Gly8-Glu22-Gly36-GLP-l(7-37)-lL-IgG4 (S228P, F234A, L235A, N297A, des K) (SEQ DD NO: 31), Cys118-Cys134-Ala167-FGF-21 (SEQ DD NO:10) in combination with Gly8-Glu22-Gly36-GLP-l(7-37)-1.5L-IgG4 (S228P) (SEQ DD NO: 32), Cys118-Cys134- Ala167-FGF-21 (SEQ DD NO: 10) in combination with Gly8-Glu22-Gly36-GLP-l(7-37)- 1.5L-IgG4 (S228P, F234A, L235A) (SEQ DD NO: 33), Cys118-Cys134-Ala167-FGF-21 (SEQ DD NO: 10) in combination with Gly8-Glu22-Gly36-GLP-l(7-37)-1.5L-IgG4 (S228P, N297A) (SEQ DD NO: 34), Cysm-Cys134-Ala167-FGF-21 (SEQ DD NO: 10) in combination with Gly8-Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, F234A, L235A, N297A) (SEQ DD NO: 35), Cys"8-Cys134-AlaI67-FGF-21 (SEQ DD NO:10) in combination with Gly8-Glu22-Gly36-GLP-l(7-37)-1.5L-IgG4 (S228P, des K) (SEQ ID NO: 36), Cys118- Cys134-Ala167-FGF-21 (SEQ DD NO: 10) in combination with Gly8-Glu22-Gly36-GLP-l(7- 37)-1.5L-IgG4 (S228P, F234A, L235A, des K) (SEQ DD NO: 37), Cys118-Cys134-Ala167- FGF-21 (SEQ DD NO:10) in combination with Gly8-Glu22-Gly36-GLP-l(7-37)-1.5L-IgG4 (S228P, N297A, des K) (SEQ DD NO: 38), Cysn8-Cys134-Ala167-FGF-21 (SEQ DD NO: 10) in combination with Gly8-Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, F234A, L235A, N297A, des K) (SEQ DD NO: 39), Cys118-Cys134-Ala167-FGF-21 (SEQ DD NO: 10) in combination with Gly8-Glu22-Gly36-GLP- 1 -2L-IgG4 (S228P) (SEQ DD NO: 40), Cys118-Cys134-Ala167-FGF-21 (SEQ DD NO: 10) in combination with Gly8-Glu22-Gly36-
27
GLP-1-2L-IgG4 (S228P, F234A, L235A) (SEQ ID NO: 41), Cys118-Cys134-Ala167-FGF- 21 (SEQ ID NO: 10) in combination with Gly8-Glu22-Gly36-GLP-1-2L-IgG4 (S228P, N297A) (SEQ ID NO: 42), Cysm-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with Gly8-Glu22-Gly36-GLP-l(7-37)-2L-IgG4 (S228P, F234A, L235A, N297A) (SEQ ID NO: 43), Cysm-Cys134-Ala167-FGF-21 (SEQ ID NO:10) in combination with Gly8-Glu22-Gly36-GLP-1-2L-IgG4 (S228P, des K) (SEQ ID NO: 44), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with Gly8-Glu22-Gly36- GLP-1-2L-IgG4 (S228P, F234A, L235A, des K) (SEQ ID NO: 45), Cys118-Cys134-Ala167- FGF-21 (SEQ ID NO: 10) in combination with Gly8-Glu22-Gly36-GLP-1-2L-IgG4 (S228P, N297A, des K) (SEQ ID NO: 46), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO:10) in combination with Gly8-Glu22-GlyM-GLP-l(7-37)-2L-IgG4 (S228P, F234A, L235A, N297A, des K) (SEQ ID NO: 47),Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with exendin-4 (SEQ ID NO: 4), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with albiglutide (SEQ ID NO: 48), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 47, Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO:10) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 47, Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 48, Cys118-Cys134-Ala167- FGF-21 (SEQ ID NO: 10) in combination with a GLP- 1 compound consisting of the amino acid sequence of SEQ ID NO: 48, Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO:10) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 49, Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ED NO: 49, Cys118-Cys134- Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 50, Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO:10) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 50, Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 51, Cys118-Cys134-Ala167- FGF-21 (SEQ ID NO: 10) in combination with a GLP- 1 compound consisting of the amino acid sequence of SEQ ED NO: 51, Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO:10)
28
in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 52, Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 52, Cys118-Cys134- Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 53, Cysm-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 53, Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 54, Cys118-Cys134-Ala167- FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 54, Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO:10) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 55, Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 55, Cys118-Cys134- Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 56, Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO:10) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 56, Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 57 and Cys118-Cys!34- Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 57.
In a preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ED NO: 17) with five additional amino acid sequence substitutions. In a preferred embodiment, the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of CysM8-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with five additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118-Cys134-
29
Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP- 1 analog comprises the amino acid sequence of Val8-Glu22-GLP-1 (SEQ DD NO: 17) with four additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF -21 analog consisting of the amino acid sequence of Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with four additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118-Cys134- Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP- 1 analog comprises an amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with three additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP-I analog consist of an amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with three additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118-Cys!34- Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP- 1 analog comprises the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with two additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with two additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118-Cys134- Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP- 1 analog comprises the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with one additional amino acid sequence substitution. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog consisting of the
30
amino acid sequence of Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with one additional amino acid sequence substitution. Preferred FGF-21 compound and GLP-I compound combinations of the present invention include, Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with VaI8-GLP-l (SEQ ID NO: 15), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Val8-Glu22-GLP-1 (SEQ ID NO: 17), Cys118-Cys134-Ala121- Ala167-FGF-21 (SEQ ID NO: 13) in combination with is Val8-Glu22-Ile33-Gly36-Pro37- Ser^^Se^-Gly^-Ala^-Pro^-Pro^-Pro^-Ser^-GLP-l (SEQ ID NO: 19), Cys118-Cys134- Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with pegylated Val8-Glu22-De33- Cys-NHΛGLP-l (SEQ ID NO: 21), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Arg34-GLP-1 (SEQ ID NO: 16), Cys1I8-Cys134-Ala121-Ala167- FGF-21 (SEQ ID NO: 13) in combination with acylated Arg34-GLP-1 (SEQ ID NO: 16), CysI18-Cys134-Ala12I-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Arg34-Lys26- (N-ε -(γ-Glu (N-α-hexadecanoyl)))-GLP-l (SEQ ID NO: 18), Cys118-Cys134-Ala121- Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P) (SEQ ID NO: 24), CysI18-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) with Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P, F234A, L235A) (SEQ ED NO: 25), Cys118- Cys134-Ala121-AlaI67-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36- GLP-1-lL-IgG4 (S228P, N297A) (SEQ ID NO: 26), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P, F234A, L235A, N297A) (SEQ ID NO: 27), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P, des K) (SEQ ID NO: 28), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) with Gly8-Glu22-Gly36-GLP- l-lL-IgG4 (S228P, F234A, L235A, des K) (SEQ DD NO: 29), Cys118-Cys134-Ala121- Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P, N297A, des K) (SEQ ID NO: 30), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ DD NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1-lL-IgG4 (S228P, F234A, L235A, N297A, des K) (SEQ DD NO: 31), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Glyg-Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P) (SEQ ID NO: 32),
31
Cysm-Cys134-Alam-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22- Gly36-GLP-1-1.5L-IgG4 (S228P, F234A, L235A) (SEQ ID NO: 33), Cys118-Cys134- Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1- 1.5L-IgG4 (S228P, N297A) (SEQ ID NO: 34), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, F234A, L235A, N297A) (SEQ ID NO: 35), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID N0:13) in combination with Gly8-Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, des K) (SEQ ID NO: 36), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, F234A, L235A, des K) (SEQ ID NO: 37), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8- Glu22-Gly36-GLP-1-1.5L-IgG4 (S228P, N297A, des K) (SEQ ID NO: 38), Cys118-Cys134- Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1- 1.5L-IgG4 (S228P, F234A, L235A, N297A, des K) (SEQ ID NO: 39), Cys118-Cys134- Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1- 2L-IgG4 (S228P) (SEQ ID NO: 40), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1-2L-IgG4 (S228P, F234A, L235A) (SEQ ID NO: 41), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1-2L-IgG4 (S228P, N297A) (SEQ ID NO: 42), Cys118- Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36- GLP-1-2L-IgG4 (S228P, F234A, L235A, N297A) (SEQ ID NO: 43), Cysll8-Cys134- Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1- 2L-IgG4 (S228P, des K) (SEQ ID NO: 44), Cys118-CysI34-Ala12I-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1-2L-IgG4 (S228P, F234A, L235A, des K) (SEQ ID NO: 45), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Glyκ-GLP-1-2L-IgG4 (S228P, N297A, des K) (SEQ ID NO: 46), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with Gly8-Glu22-Gly36-GLP-1-2L-IgG4 (S228P, F234A, L235A, N297A, des K) (SEQ ID NO: 47), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with exendin- 4 (SEQ ID NO: 4), Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with albiglutide (SEQ ID NO: 49), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO:10) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID
32
NO: 47, Cysπ8-Cys134-Ala167-FGF-21 (SEQ ID NO: 10) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ DD NO: 47, Cys1 I8-Cys134- Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 48, Cys118-Cys134-Ala121-Ala167- FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 48, Cysm-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 49, Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 49, Cysm-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP- 1 compound comprising the amino acid sequence of SEQ ID NO: 50, Cys118-Cys134-Ala121- Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 50, Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 51, Cys1 I8-Cys134-Ala121-AlaI67-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 51, Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 52, Cys118- Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 52, Cys118-CysI34-Ala121-Ala167- FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 53, Cys1 I8-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ED NO: 53, Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ED NO: 54, Cys118-
Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 54, Cysn8-Cys134-Ala121-Ala167- FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 55, Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 55, Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in
33
combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 56, Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 56, Cys118- Cys134-Ala121-Ala167-FGF-21 (SEQ DD NO: 13) in combination with a GLP-I compound comprising the amino acid sequence of SEQ ID NO: 57, and Cys118-Cys134-Ala121-Ala167- FGF-21 (SEQ ID NO: 13) in combination with a GLP-I compound consisting of the amino acid sequence of SEQ ID NO: 57.
In a preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118-Cys134-Ala!21-Ala167-FGF- 21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with five additional amino acid sequence substitutions. In a preferred embodiment, the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP- 1 analog, wherein the GLP- 1 analog consists of the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with five additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118- Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val8-Glu22-GLP-l (SEQ ID NO: 17) with four additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with four additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118-Cysl34-Ala12I-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val8-Glu22- GLP-I (SEQ ID NO: 17) with three additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an
34
FGF-21 analog consisting of the amino acid sequence of Cysm-Cys134-Ala121-Ala167- FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with three additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with two additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys118-Cy s134- Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) with two additional amino acid sequence substitutions. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog comprising the amino acid sequence of Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog comprises the amino acid sequence of Val8-Glu22-GLP-1 (SEQ ID NO: 17) comprises one additional amino acid sequence substitution. In another preferred embodiment, the combination of the present invention comprises an FGF-21 analog consisting of the amino acid sequence of Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13) in combination with a GLP-I analog, wherein the GLP-I analog consists of the amino acid sequence of Val8-Glu22- GLP-I (SEQ ID NO: 17) comprises one additional amino acid sequence substitution.
Example 1 -Effect of combination treatment with GLP-I and FGF-21 on body weight and on blood glucose levels
Diet-induced obese (DIO) male C57/B16 mice (Harlan: Virginia) maintained on a calorie rich diet (TD95217, Teklad, Madison, WI) since weaning are used. DIO is established by ad libitum feeding for at least 7 weeks of a diet consisting of 40% fat, 39% carbohydrate, and 21% protein caloric content (TD95217). Animals are individually housed in a temperature-controlled (24°C) facility with 12 hour light/dark cycle (lights on
35
2200) and free access to food (TD95217) and water. After a minimum of 2 weeks acclimation to the facility, the mice are randomized according to their body weight, so each experimental group of animals would have similar body weight.
Body composition of DIO male C57/B16 mice is determined by using QNMR analysis 1 day prior to initiation of treatment. Combination treatment is administered with two delivery methods. A FGF-21 compound (1 mg/kg) is subcutaneously injected once a day and a GLP-I compound (3 nmol/kg/day) is delivered by continuous subcutaneous infusion with alzet pump. The experimental groups are as follow: One group ("Vehicle") of mice (n=8) receives PBS (11.4 μL/day) and a daily subcutaneous injection of 0.05 mL/lOg of PBS. Another group ("FGF-21") of mice (n=8) receives 11.4 μL/day of PBS using the alzet pump and a daily subcutaneous injection of 1 mg/kg of FGF-21. The "GLP- 1 " group of mice receives 3 nmol/kg/day of a GLP- 1 compound through an alzet pump and a daily subcutaneous injection of 0.05mL/10g of PBS. The "GLP-I + FGF-21" group of mice receives 3 nmol/kg/day of a GLP-I compound through an alzet pump and a daily subcutaneous injection of 1 mg/kg of a FGF-21 compound. Injections occur prior to the onset of the dark photoperiod. Starting weight values are measured after implantation of alzet pumps on Day 1. Body weights are recorded in conjunction with daily dosing. Average weight changes compared to starting weights of a particular treatment group, including vehicle, are determined. Average daily weight changes are normalized to average of daily weight change of Vehicle group and are reported in Table 1 (i.e., (Average weight change of Treatment group) - (Average weight change of Vehicle group)). For all treatment groups n=8.
Data in Table 1 represent results where the FGF-21 compound is human FGF-21 (SEQ ID NO: 1) and where the GLP-I compound is Val^Glu^-Ile^-Gly^-Pro^-Ser38- Ser^-Gly^-Ala^-Pro^-Pro^-Pro^-Ser^-GLP-l (SEQ ID NO: 19). The data demonstrate that the use of a FGF-21 compound in combination with a GLP-I compound results in a synergistic effect on weight loss.
Table 1- Average Weight Change Normalized to Vehicle Treated Mice
36
Claims
1. The use of an FGF-21 compound and a GLP- 1 compound in the manufacture of a medicament for lowering body weight.
2. The use of an FGF-21 compound and a GLP- 1 compound in the manufacture of a medicament for the treatment of obesity.
3. The use according to claim 1 or claim 2, wherein the FGF-21 compound is an FGF-21 analog.
4. The use according to claim 3, wherein the FGF-21 compound is selected from the group consisting of Cys118-Cys134-FGF-21 (SEQ ED NO: 9), Cys118-Cys134-Ala167- FGF-21 (SEQ ID NO: 10), Cys21-Cys33-Ala167-FGF-21 (SEQ ID NO: 11), Cys26- CysI22-Ala167-FGF-21 (SEQ ID NO: 12), and Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13).
5. The use according to claim 4, wherein the FGF-21 compound is Cys118-Cys134-
Ala167-FGF-21 (SEQ ID NO: 10).
6. The use according to claim 4, wherein the FGF-21 compound is Cys118-Cys134- Ala121-Ala167-FGF-21 (SEQ ID NO: 13).
7. The use according to any one of claims 1-6, wherein the GLP-I compound is a GLP-I analog.
8. The use according to claim 7, wherein the GLP-I analog comprises an amino acid sequence of
His Xaa Glu Gly Thr Phe Thr Ser Asp VaI Ser Ser 10 15
Tyr Leu Glu Xaa Gln Ala Ala Lys Glu Phe lie Ala 20 25 30
Trp Leu Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 Xaa Xaa Xaa
45 38
wherein
Xaa at position 8 is Gly, Ala, VaI,
Xaa at position 22 is Gly, Glu, Asp, or Lys,
Xaa at position 33 is VaI, or He, Xaa at position 34 is Lys or Arg,
Xaa at position 36 is Arg or Gly,
Xaa at position 37 is selected from the group consisting of NH2, Gly and Pro,
Xaa at position 38 is Ser or absent,
Xaa at position 39 is Ser or absent, Xaa at position 40 is Gly or absent,
Xaa at position 41 is Ala or absent,
Xaa at position 42 is Pro or absent,
Xaa at position 43 is Pro or absent,
Xaa at position 44 is Pro or absent, and Xaa at position 45 is Ser or absent. (SEQ ID NO: 14)
9. The use according to claim 8, wherein the GLP-I analog comprises the amino acid sequence of Val^Glu∞-GLP-l (SEQ ID NO: 17).
10. The use according to claim 8, wherein the GLP-I analog comprises the amino acid sequence of Val^Glu^-Ile^-Gly^-Pro^-Se^^Se^-Gly^-Ala^-Pro^-Pro43-
Pro^-Ser^-GLP-l (SEQ ID NO: 19).
11. The use according to any one of claims 1-6, wherein the GLP-I compound is a GLP-derivative.
12. The use according to claim 11, wherein the GLP-I derivative comprises an amino acid sequence of
His Xaa Glu Gly Thr Phe Thr Ser Asp VaI Ser Ser
10 15
Tyr Leu Glu Xaa Gln Ala Ala Lys Glu Phe lie Ala 20 25 30
Trp Leu Xaa Lys Gly Gly Pro Ser Ser Gly Ala Pro 39
35 40
Pro Pro Cys Xaa
45 wherein Xaa at position 8 is: D-Ala, Gly, VaI, Leu, lie, Ser, or Thr; Xaa at position 22 is: Gly, Glu, Asp, or Lys; Xaa at position 33 is: VaI or De Xaa at position 46 is: Cys or CyS-NH2 and wherein one PEG molecule is covalently attached to Cys45 and one PEG molecule is covalently attached to Cys46 or CyS^-NH2. (SEQ ID NO: 20)
13. The use according to any one of claims 1-6, wherein the GLP-I compound is a GLP-I fusion protein.
14. The use according to claim 13, wherein the GLP-I fusion protein comprises a GLP-I peptide and the Fc portion of an immunoglobulin wherein the GLP-I peptide comprises an amino acid sequence of
His Xaa Glu Gly Thr Phe Thr Ser Asp VaI Ser Ser
10 15 Tyr Leu Glu Glu Gln Ala Ala Lys Glu Phe He Ala
20 25 30
Trp Leu Xaa Xaa Gly Gly Xaa
35
wherein
Xaa at position 8 is Gly or VaI;
Xaa at position 33 is VaI or Lys;
Xaa at position 34 is Lys or Asn; Xaa at position 37 is Gly, Pro or is absent, (SEQ ID NO:22) 40
and wherein the GLP analog is fused to the Fc portion of an immunoglobulin comprising the amino acid sequence of
Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys
5 10 Pro Ala Pro Xaa Xaa Xaa Gly Gly Pro Ser VaI Phe
15 20
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie 25 30 35
Ser Arg Thr Pro Glu VaI Thr Cys VaI VaI VaI Asp 40 45
VaI Ser Gln Glu Asp Pro Glu VaI Gln Phe Asn Trp
50 55 60
Tyr VaI Asp Gly VaI Glu VaI His Asn Ala Lys Thr
65 70 Lys Pro Arg Glu Glu Gln Phe Xaa Ser Thr Tyr Arg
75 80
VaI VaI Ser VaI Leu Thr VaI Leu His Gln Asp Trp 85 90 95
Leu Asn Gly Lys Glu Tyr Lys Cys Lys VaI Ser Asn 100 105
Lys Gly Leu Pro Ser Ser lie Glu Lys Thr lie Ser
110 115 120
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln VaI Tyr
125 130 Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn 41
135 140
Gln VaI Ser Leu Thr Cys Leu VaI Lys Gly Phe Tyr 145 150 155
Pro Ser Asp lie Ala VaI Glu Trp Glu Ser Asn Gly 160 165
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro VaI
170 175 180
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
185 190 Leu Thr VaI Asp Lys Ser Arg Trp Gln Glu Gly Asn
195 200
VaI Phe Ser Cys Ser VaI Met His Glu Ala Leu His 205 210 215
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu 220 225
Gly Xaa 230 wherein:
Xaa at position 16 is Pro or Glu; Xaa at position 17 is Phe, VaI, or Ala; Xaa at position 18 is Leu, Glu, or Ala; Xaa at position 80 is Asn or Ala; and Xaa at position 230 is Lys or is absent. (SEQ ID NO: 23) 42
The use according to claim 14, wherein the GLP-I fusion protein further comprises a linker, wherein the linker comprises an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO;7, and SEQ ID NO:8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17180108.7A EP3260129A1 (en) | 2007-08-03 | 2008-07-30 | An fgf-21 compound and a glp-1 compound for use in the treatment of obesity |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95378507P | 2007-08-03 | 2007-08-03 | |
| PCT/US2008/071508 WO2009020802A2 (en) | 2007-08-03 | 2008-07-30 | Treatment for obesity |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17180108.7A Division EP3260129A1 (en) | 2007-08-03 | 2008-07-30 | An fgf-21 compound and a glp-1 compound for use in the treatment of obesity |
| EP17180108.7A Division-Into EP3260129A1 (en) | 2007-08-03 | 2008-07-30 | An fgf-21 compound and a glp-1 compound for use in the treatment of obesity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2185178A2 true EP2185178A2 (en) | 2010-05-19 |
| EP2185178B1 EP2185178B1 (en) | 2017-08-23 |
Family
ID=40243880
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17180108.7A Withdrawn EP3260129A1 (en) | 2007-08-03 | 2008-07-30 | An fgf-21 compound and a glp-1 compound for use in the treatment of obesity |
| EP08796800.4A Active EP2185178B1 (en) | 2007-08-03 | 2008-07-30 | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17180108.7A Withdrawn EP3260129A1 (en) | 2007-08-03 | 2008-07-30 | An fgf-21 compound and a glp-1 compound for use in the treatment of obesity |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20110034373A1 (en) |
| EP (2) | EP3260129A1 (en) |
| JP (1) | JP2010535781A (en) |
| CA (1) | CA2693504A1 (en) |
| ES (1) | ES2646614T3 (en) |
| WO (1) | WO2009020802A2 (en) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| JOP20190083A1 (en) | 2008-06-04 | 2017-06-16 | Amgen Inc | Fgf21 mutant fusion polypeptides and uses thereof |
| MX341149B (en) | 2008-10-10 | 2016-08-09 | Amgen Inc | Fgf21 mutants and uses thereof. |
| US9480753B2 (en) | 2009-01-23 | 2016-11-01 | Novo Nordisk A/S | FGF21 derivatives with albumin binder A-B-C-D-E- and their use |
| AU2010246038A1 (en) | 2009-05-05 | 2011-12-01 | Amgen Inc. | FGF21 mutants and uses thereof |
| SI3248610T1 (en) | 2009-05-05 | 2024-03-29 | Amgen Inc., | Fgf21 mutants and uses thereof |
| US20120172298A1 (en) * | 2009-06-11 | 2012-07-05 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
| WO2011154349A2 (en) * | 2010-06-08 | 2011-12-15 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
| WO2010148142A1 (en) | 2009-06-17 | 2010-12-23 | Amgen Inc. | Chimeric fgf19 polypeptides and uses thereof |
| CN101993496B (en) * | 2009-08-20 | 2013-06-05 | 重庆富进生物医药有限公司 | Dual blood sugar and blood fat adjusting fusion protein and preparation method and application thereof |
| CN101993485B (en) * | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof |
| AU2010326024A1 (en) | 2009-12-02 | 2012-07-05 | Amgen Inc. | Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho |
| UA109888C2 (en) | 2009-12-07 | 2015-10-26 | ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES | |
| EP2359843A1 (en) * | 2010-01-21 | 2011-08-24 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| WO2011130417A2 (en) | 2010-04-15 | 2011-10-20 | Amgen Inc. | HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS |
| JP6034781B2 (en) | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination therapy |
| CN103124562A (en) * | 2010-06-08 | 2013-05-29 | 诺沃—诺迪斯克有限公司 | FGF21 analogues and derivatives |
| US8440797B2 (en) | 2010-12-06 | 2013-05-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
| CA2820134A1 (en) * | 2010-12-06 | 2012-06-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20130035298A1 (en) | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| EP2548570A1 (en) * | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| UY34347A (en) | 2011-09-26 | 2013-04-30 | Novartis Ag | DUAL FUNCTION PROTEINS TO TREAT METABOLIC DISORDERS |
| ES2623786T3 (en) | 2011-12-22 | 2017-07-12 | Pfizer Inc. | Purification procedure of an H38C2 antibody sample |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| SI2814842T1 (en) | 2012-02-15 | 2018-10-30 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
| EP3196214B1 (en) | 2012-02-15 | 2019-07-31 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
| EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| ES2929025T3 (en) | 2012-05-14 | 2022-11-24 | Boehringer Ingelheim Int | Linagliptin, a xanthine derivative as a dpp-4 inhibitor, for use in the treatment of SIRS and/or sepsis |
| WO2013174768A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada |
| TWI641687B (en) * | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | Production cell line enhancers |
| AR092076A1 (en) * | 2012-08-22 | 2015-03-18 | Lilly Co Eli | HOMODIMERIC PROTEINS |
| MX2015002985A (en) * | 2012-09-07 | 2015-06-22 | Sanofi Sa | Fusion proteins for treating a metabolic syndrome. |
| UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
| AU2013366691A1 (en) | 2012-12-21 | 2015-07-09 | Sanofi | Exendin-4 derivatives |
| TW201609799A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Dual GLP-1/GIP receptor agonists |
| TW201609797A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609796A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Non-acylated EXENDIN-4 peptide analogues |
| BR112016017402A2 (en) | 2014-02-21 | 2017-10-17 | Medimmune Ltd | anti-pcsk9 ~ glp-1 fusions and methods for use |
| EP3125921B1 (en) | 2014-03-11 | 2020-07-08 | Novartis AG | Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy |
| TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
| TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
| TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| JP6738316B2 (en) | 2014-07-17 | 2020-08-12 | ノヴォ ノルディスク アクティーゼルスカブ | Site-directed mutagenesis of TREM-1 antibody to reduce viscosity |
| TWI681966B (en) | 2014-12-23 | 2020-01-11 | 丹麥商諾佛 儂迪克股份有限公司 | Fgf21 derivatives and uses thereof |
| AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
| TW201706291A (en) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
| KR20170049319A (en) | 2015-10-28 | 2017-05-10 | 주식회사유한양행 | Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same |
| KR20170049320A (en) | 2015-10-28 | 2017-05-10 | 주식회사유한양행 | Dual function proteins and pharmaceutical composition comprising the same |
| US10385113B2 (en) | 2016-03-30 | 2019-08-20 | The Board Of Trustees Of The University Of Arkansas | Engineered FGF compositions and methods of use thereof |
| MX2019005380A (en) | 2016-11-10 | 2019-08-12 | Yuhan Corp | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins. |
| JP7181886B2 (en) * | 2017-03-14 | 2022-12-01 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | A dual targeting fusion protein comprising the Fc portion of an immunoglobulin |
| EP3612637A4 (en) * | 2017-04-21 | 2021-01-27 | Yuhan Corporation | Method for producing dual function proteins and its derivatives |
| IL273253B1 (en) | 2017-09-22 | 2024-03-01 | Regeneron Pharma | Glucagon-like peptide 1 receptor agonists and uses thereof |
| CN109836504B (en) * | 2017-11-24 | 2022-08-02 | 浙江道尔生物科技有限公司 | Multi-domain active protein for treating metabolic diseases |
| CN109836503B (en) * | 2017-11-24 | 2022-09-16 | 浙江道尔生物科技有限公司 | Multiple active protein for treating metabolic diseases |
| CN111518770B (en) * | 2017-12-19 | 2023-01-06 | 北京吉源生物科技有限公司 | Stem cell for expressing GLP1 and FGF21 and application thereof |
| WO2019154189A1 (en) | 2018-02-08 | 2019-08-15 | Sunshine Lake Pharma Co., Ltd. | Fgf21 variant, fusion protein and application thereof |
| US11267855B2 (en) | 2018-03-16 | 2022-03-08 | The Board Of Trustees Of The University Of Arkansas | Engineered FGF1 and FGF2 compositions and methods of use thereof |
| US11155618B2 (en) | 2018-04-02 | 2021-10-26 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
| SG11202101904UA (en) * | 2018-09-14 | 2021-04-29 | Univ Leland Stanford Junior | Spd-1 variant - fc fusion proteins |
| CN110964116A (en) * | 2018-09-26 | 2020-04-07 | 北京辅仁瑞辉生物医药研究院有限公司 | GLP1-Fc fusion proteins and conjugates thereof |
| CN112279920B (en) * | 2019-07-25 | 2024-01-16 | 安源医药科技（上海）有限公司 | FGF21Fc fusion protein, GLP-1Fc fusion protein, combined therapeutic agent and application thereof |
| CN113728013B (en) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Conjugates of fusion proteins of GLP-1 and FGF21 |
| WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA65549C2 (en) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
| ATE346093T1 (en) | 2000-06-16 | 2006-12-15 | Lilly Co Eli | ANALOGUE OF GLUCAGON-LIKE PEPTIDE-1 |
| CA2434237C (en) | 2000-12-07 | 2012-05-15 | Eli Lilly And Company | Glp-1 fusion proteins |
| WO2003011213A2 (en) * | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Method for treating diabetes and obesity |
| MXPA04001525A (en) * | 2001-08-23 | 2004-05-31 | Lilly Co Eli | Glucagon-like peptide-1 analogs. |
| CA2468700A1 (en) | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
| AU2004251145C1 (en) | 2003-06-12 | 2011-04-14 | Eli Lilly And Company | GLP-1 analog fusion proteins |
| EP1702067A1 (en) | 2003-12-10 | 2006-09-20 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| EP1727559A1 (en) * | 2004-01-26 | 2006-12-06 | Eli Lilly And Company | Use of fgf-21 and a thiazolidinedione for treating type 2 diabetes |
| WO2005113606A2 (en) | 2004-05-13 | 2005-12-01 | Eli Lilly And Company | Fgf-21 fusion proteins |
| WO2006028595A2 (en) * | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| WO2006028714A1 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| US8183340B2 (en) * | 2005-05-13 | 2012-05-22 | Eli Lilly And Company | GLP-1 pegylated compounds |
| KR101476472B1 (en) * | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | Modified fgf-21 polypeptides and their uses |
-
2008
- 2008-07-30 EP EP17180108.7A patent/EP3260129A1/en not_active Withdrawn
- 2008-07-30 EP EP08796800.4A patent/EP2185178B1/en active Active
- 2008-07-30 US US12/668,475 patent/US20110034373A1/en not_active Abandoned
- 2008-07-30 JP JP2010520138A patent/JP2010535781A/en not_active Withdrawn
- 2008-07-30 CA CA2693504A patent/CA2693504A1/en not_active Abandoned
- 2008-07-30 ES ES08796800.4T patent/ES2646614T3/en active Active
- 2008-07-30 WO PCT/US2008/071508 patent/WO2009020802A2/en active Application Filing
-
2012
- 2012-06-27 US US13/534,322 patent/US8557769B2/en not_active Expired - Fee Related
-
2013
- 2013-10-03 US US14/045,174 patent/US20140024586A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2009020802A3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20140024586A1 (en) | 2014-01-23 |
| ES2646614T3 (en) | 2017-12-14 |
| WO2009020802A3 (en) | 2009-10-29 |
| EP3260129A1 (en) | 2017-12-27 |
| JP2010535781A (en) | 2010-11-25 |
| CA2693504A1 (en) | 2009-02-12 |
| US20110034373A1 (en) | 2011-02-10 |
| WO2009020802A2 (en) | 2009-02-12 |
| US20120264683A1 (en) | 2012-10-18 |
| US8557769B2 (en) | 2013-10-15 |
| EP2185178B1 (en) | 2017-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8557769B2 (en) | Co-administration of FGF-21 and GLP-1 to treat diabetes and lower blood glucose | |
| EP3156066B1 (en) | Composition for treating diabetes, containing long-acting insulin analog conjugate and long-acting insulin secretion peptide conjugate | |
| RU2606840C2 (en) | Composition for treating diabetes, containing long-acting insulin conjugate and long-acting insulinotropic peptide conjugate | |
| JP5890085B2 (en) | Glucagon analogues exhibiting improved solubility in physiological pH buffers | |
| AU2005207870B2 (en) | The combined use of GLP-1 agonists and gastrin for regulating blood glucose levels | |
| US7595294B2 (en) | Vasoactive intestinal polypeptide pharmaceuticals | |
| EP2487184A1 (en) | Glucagon/GLP-1 receptor co-agonists | |
| WO2020207477A1 (en) | Glp-1 and gip receptor dual agonist compounds and use thereof | |
| CN101993485A (en) | Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof | |
| WO2021239082A1 (en) | Dual-agonist compound for both glp-1 and gip receptors and application thereof | |
| KR20170078668A (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| WO2021093883A1 (en) | Dual receptor-acting agonist compounds and pharmaceutical composition thereof | |
| EP3900735A1 (en) | Pharmaceutical composition comprising insulin and triple agonist having activity with respect to all of glucagon and glp-1 and gip receptor | |
| CN113105561B (en) | Preparation method and application of double-target fusion protein | |
| CN109195983B (en) | Conjugates of islet neogenesis polypeptides and analogs and methods thereof | |
| KR20200078414A (en) | A pharmaceutical composition comprising insulin and glucagon | |
| NZ726959B2 (en) | Composition for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate | |
| MXPA06008394A (en) | The combined use of glp-1 agonists and gastrin for regulating blood glucose levels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GLAESNER, WOLFGANG Inventor name: COSKUN, TAMER |
|
| 17P | Request for examination filed |
Effective date: 20100429 |
|
| RAX | Requested extension states of the european patent have changed |
Extension state: BA Payment date: 20100429 Extension state: MK Payment date: 20100429 Extension state: RS Payment date: 20100429 Extension state: AL Payment date: 20100429 |
|
| RBV | Designated contracting states (corrected) |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
| 17Q | First examination report despatched |
Effective date: 20130724 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20160819 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| INTC | Intention to grant announced (deleted) | ||
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20170307 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 920617 Country of ref document: AT Kind code of ref document: T Effective date: 20170915 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008051784 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2646614 Country of ref document: ES Kind code of ref document: T3 Effective date: 20171214 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20170823 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 920617 Country of ref document: AT Kind code of ref document: T Effective date: 20170823 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171123 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171124 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171223 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171123 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008051784 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20180524 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180730 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20180731 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180731 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180731 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180731 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180730 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180730 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20080730 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230419 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230620 Year of fee payment: 16 Ref country code: FR Payment date: 20230621 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230620 Year of fee payment: 16 Ref country code: ES Payment date: 20230801 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230620 Year of fee payment: 16 |